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Abstract
Aims: To estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) disease severity, and
iv) mortality from SARS-CoV-2/COVID-19 disease. 
 
Design: Living rapid review of observational and experimental studies with random-effects hierarchical Bayesian meta-
analyses. Published articles and pre-prints were identified via MEDLINE and medRxiv.
 
Setting: Community or hospital. No restrictions on location.
 
Participants: Adults who received a SARS-CoV-2 test or a COVID-19 diagnosis.
 
Measurements: Outcomes were SARS-CoV-2 infection, hospitalisation, disease severity and mortality stratified by
smoking status. Study quality was assessed (i.e. ‘good’, ‘fair’ and ‘poor’).
 
Findings: Version 9 (searches up to 27 October 2020) included 279 studies with 42 ‘good’ and ‘fair’ quality studies
included in unadjusted meta-analyses. Seventy-nine studies (28%) reported current, former and never smoking status
with the remainder using broader categories. Recorded smoking prevalence among people with COVID-19 was
generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-CoV-2
infection (RR = 0.69, 95% Credible Interval (CrI) = 0.57-0.83, τ = 0.38). Data for former smokers were inconclusive (RR
= 1.02, 95% CrI = 0.93-1.12, τ = 0.18) but favoured there being no important association (5% probability of RR ≥1.1).
Former compared with never smokers were at somewhat increased risk of hospitalisation (RR = 1.17, CrI = 1.04-1.36, τ
= 0.17), greater disease severity (RR = 1.52, CrI = 1.12-2.06, τ = 0.29) and mortality (RR = 1.39, 95% CrI = 1.16-1.69, τ
= 0.23). Data for current smokers on hospitalisation, disease severity and mortality were inconclusive (RR = 1.06, CrI =
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0.89-1.27, τ = 0.23; RR = 1.26, CrI = 0.86-1.94, τ = 0.34; RR = 1.05, 95% CrI = 0.71-1.49, τ = 0.45, respectively) but
favoured there being no important associations with hospitalisation and mortality (32% and 39% probability of RR ≥1.1,
respectively) and a small but important association with disease severity (80% probability of RR ≥1.1). 
 
Conclusions: Compared with never smokers, current smokers appear to be at reduced risk of SARS-CoV-2 infection
while former smokers appear to be at increased risk of hospitalisation, greater disease severity and mortality from
COVID-19. However, it is uncertain whether these associations are causal.
 
v7 of this living review article has been published in Addiction and is available here https://doi-
org.libproxy.ucl.ac.uk/10.1111/add.15276 
Introduction
 
COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Large age and gender differences in case severity
and mortality have been observed in the ongoing COVID-19 pandemic1; however, these differences are currently
unexplained. SARS-CoV-2 enters epithelial cells through the angiotensin-converting enzyme 2 (ACE-2) receptor2. Some
evidence suggests that gene expression and subsequent receptor levels are elevated in the airway and oral epithelium of
current smokers3,4, which could put smokers at higher risk of contracting SARS-CoV-2. Other studies, however, suggest
that nicotine downregulates the ACE-2 receptor5. These uncertainties notwithstanding, both former and current smoking is
known to increase the risk of respiratory viral6,7 and bacterial8,9 infections and is associated with worse outcomes once
infected. Cigarette smoke reduces the respiratory immune defence through peri-bronchiolar inflammation and fibrosis,
impaired mucociliary clearance and disruption of the respiratory epithelium10. There is also reason to believe that
behavioural factors (e.g. regular hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 infection and
transmission in current smokers. However, early data from the COVID-19 pandemic have not provided clear evidence for a
negative impact of current or former smoking on SARS-CoV-2 infection or COVID-19 disease outcomes, such as
hospitalisation or mortality11. It has also been hypothesised that nicotine might protect against a hyper-inflammatory
response to SARS-CoV-2 infection, which may lead to adverse outcomes in patients with COVID-19 disease12.
 
There are several reviews that fall within the scope of smoking and COVID-1911,13–18. We aimed to produce a rapid
synthesis of available evidence pertaining to the rates of infection, hospitalisation, disease severity and mortality from
SARS-CoV-2/COVID-19 stratified by smoking status. Given the increasing availability of data on this topic, this is a living
review with regular updates. As evidence accumulates, the review will be expanded to include studies reporting COVID-19
outcomes by alternative nicotine use (e.g., nicotine replacement therapy or e-cigarettes).
 
Methods
 
Study design
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This is a living evidence review which is updated as new evidence becomes available19. We adopted recommended best
practice for rapid evidence reviews, which involved limiting the search to main databases and having one reviewer extract
the data and another verify20. This study was not pre-registered but evolved from a report written for a UK medical
society21. The most recent (and all future) version(s) of this living review is available here
(https://www.qeios.com/read/latest-UJR2AW). Version 7 of this living review has been published in a peer-reviewed
journal22. A completed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist is
included in Supplementary file 1.
 
Eligibility criteria
 
Studies were included if they:
 
1. Were primary research studies using experimental (e.g. randomised controlled trial), quasi-experimental (e.g. pre- and
post-test) or observational (e.g. case-control, retrospective cohort, prospective cohort) study designs;
2. Included adults aged 16+ years;
3. Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody assays), ii) clinical diagnosis of
COVID-19, iii) hospitalisation with COVID-19, iv) severity of COVID-19 disease in those hospitalised or v) mortality from
COVID-19; 
4. Reported any of the outcomes of interest by self-reported or biochemically verified smoking status (e.g. current smoker,
former smoker, never smoker) or current vaping and nicotine replacement therapy (NRT) use;
5. Were available in English;
6. Were published in a peer-reviewed journal, as a pre-print or a public health report by reputable bodies (e.g.
governments, scientific societies).
 
Search strategy
 
The following terms were searched for in Ovid MEDLINE (2019-search date) as free text or Medical Subject Headings:
 
1. Tobacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or Smoking/ or Smoking Pipes/ or Cigar Smoking/
or Smoking Prevention/ or Cigarette Smoking/ or smoking.mp. or Pipe Smoking/ or Smoking, Non-Tobacco Products/
or Smoking Water Pipes/
2. Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine Chewing Gum/
3. vaping.mp. or Vaping/
4. 1 or 2 or 3
5. Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or covid.mp.
6. 4 and 5
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The following terms were searched for in titles, abstracts and full texts in medRxiv (no time limitations):
 
1. covid (this term captures both covid and SARS-CoV-2) AND smoking
2. covid AND nicotine
3. covid AND vaping
 
Additional articles/reports of interest were identified through mailing lists, Twitter, the International Severe Acute
Respiratory and Emerging Infection Consortium (ISARIC) and the US Centers for Disease Control and Prevention (CDC).
Where updated versions of pre-prints or public health reports were available, old versions were superseded.
 
Selection of studies
 
One reviewer screened titles, abstracts and full texts against the inclusion criteria.
 
Data extraction
 
Data were extracted by one reviewer and verified (i.e. independently checked against pre-prints and published reports) by
another on i) author (year); ii) date published; iii) country; iv) study design; v) study setting; vi) sample size; vii) sex; viii)
age; ix) smoking status (e.g. current, former, never, not stated, missing) and whether it was biochemically verified; x) use of
alternative nicotine products; xi) SARS-CoV-2 testing; xii) SARS-CoV-2 infection; xiii) diagnosis of COVID-19; xiv)
hospitalisation with COVID-19; xv) disease severity in those hospitalised with COVID-19; xvi) mortality; xvii) adjustment of
smoking specific risk estimates for relevant covariates (e.g. age, sex); and xviii) whether a representative or random
sampling method was used.
 
Quality appraisal
 
The quality of included studies was assessed to determine suitability for inclusion in meta-analyses. Studies were judged
as ‘good’ quality if they: i) had <20% missing data on smoking status and used a reliable self-report measure that
distinguished between current, former and never smoking status; AND ii) used biochemical verification of smoking status
and reported results from adjusted analyses; OR reported data from a representative/random sample. Studies were rated
as ‘fair’ if they fulfilled only criterion i) and were otherwise rated as ‘poor’. The quality appraisal was conducted by one
reviewer and verified by a second. 
 
Evidence synthesis
 
A narrative synthesis was conducted. Data from ‘good’ and ‘fair’ quality studies were pooled in R v.3.6.323. In a living
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review where new data are regularly added to the analyses, it may be more appropriate to use a Bayesian (as opposed to
frequentist) approach where prior knowledge is used in combination with new data to estimate a posterior risk distribution.
A Bayesian approach mitigates the issue of performing multiple statistical tests, which can inflate family-wise error. A
series of random-effects hierarchical Bayesian meta-analyses were performed with the brms24 package to estimate the
relative risk for each comparison with accompanying 95% credible intervals (CrIs). We first defined prior distributions for
the true pooled effect size (µ) and the between-study heterogeneity (τ), with µ specified as a normal distribution with a
mean equal to the derived point estimate from each comparison of interest in the immediately preceding version of this
living review25, and τ specified as a half-Cauchy distribution with a mean of 0 and standard deviation of 1. The half-
Cauchy distribution was selected to reflect prior knowledge that high levels of between-study heterogeneity are more likely
than lower levels. Markov Chain Monte Carlo methods (20,000 burn-ins followed by 80,000 iterations) were then used to
generate a risk distribution for each study, in addition to a pooled effect for the posterior risk distribution. We report forest
plots with the pooled effect for the posterior risk distribution displayed as the median relative risk with an accompanying
95% CrIs. We used the empirical cumulative distribution function (ECDF) to estimate the probability of there being a 10%
reduction or 10% increase in relative risk (RR) (i.e. RR ≥1.1 or RR ≤0.9). Due to a lack of indication as to what constitutes a
clinically or epidemiologically meaningful effect (e.g. with regards to onward disease transmission or requirements for
intensive care beds), we deemed a 10% change in risk as small but important. Where data were inconclusive (as indicated
by CrIs crossing RR = 1.0), to disambiguate whether data favoured no effect or there being a small but important
association, we estimated whether there was ≥75% probability of RR ≥1.1 or RR ≤0.9.
Two sensitivity analyses were performed. First, a minimally informative prior for µ was specified as a normal distribution
with a mean of 0 and standard deviation of 1 and τ as described above. Second, an informative prior as described above
for µ was used with τ specified as a half-Cauchy distribution with a mean of 0.3 and standard deviation of 1 to reflect
greater between-study heterogeneity.
To aid in the visualisation of smoking prevalence in the included studies, the weighted mean prevalence of current and
former smoking was calculated for countries with ≥3 studies and plotted for comparison with national prevalence
estimates. It should be noted that prevalence estimates in the included studies were not adjusted for age, sex,
socioeconomic position, or geographic region within countries.
Results
 
In the current review version (v9) with searches up to 27 October 2020, a total of 680 records were identified, with 279
studies included in a narrative synthesis and 42 studies included in meta-analyses (see Figure 1).
 
Figure 1. PRISMA flow diagram of included studies.
 
Study characteristics
 
Characteristics of included studies are presented in Table 1. Studies were conducted across 34 countries. Seventy-eight
studies were conducted in the US, 57 in China, 31 in the UK, 16 in Spain, 14 in France and Mexico, nine in Italy, eight
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across multiple international sites, five in Brazil and Iran, four in Israel, three in Turkey, two in Australia, Bangladesh, Chile,
Colombia, Denmark, Finland, Germany, India, Japan, the Netherlands and Qatar and one from 13 further countries (see
Supplementary figure S1). The majority of studies used observational designs (see Supplementary table S1). One-
hundred-and-seventy-nine studies (64%) were conducted in hospital settings, 77 studies (28%) included a community
component in addition to hospitalised patients, 21 studies (8%) were conducted exclusively in the community, with one
remaining study conducted in a quarantine centre and one study did not state the study setting. Studies had a median of
432 (interquartile range = 132-1,854) participants. The majority of studies (89%) used reverse transcriptase polymerase
chain reaction (RT-PCR) for confirmation of SARS-CoV-2 infection, 5.7% used an antibody test to confirm prior infection
and 5.3% of studies relied on a combination of RT-PCR and clinical diagnosis (see Supplementary table S1).
 
Smoking status
 
Categorisation of smoking status was heterogeneous (see Table 1). One-hundred-and-seventy studies collected data on
smoking status through routine electronic health records (EHRs), 80 studies used a bespoke case report form for COVID-
19 and 29 studies did not state the source for information on smoking status. None of the studies verified smoking status
biochemically. Notably, only 79 (28%) studies reported current, former and never smoking status (see Supplementary table
S2a), with a further 18 studies reporting ever and never smoking status (see Supplementary table S2b). The remaining 182
studies reported current, current/former or current and former smoking status but did not explicitly state whether remaining
participants were never smokers or if data were missing on smoking status (see Supplementary table S2c). Ninety-four
studies explicitly reported the proportion with missing data on smoking status, which ranged from 0% to 96%. 
 
Use of alternative nicotine products
 
Five studies recorded the use of alternative nicotine products in current and/or former smokers but did not report COVID-19
outcomes stratified by alternative nicotine use26–30.
 
Quality appraisal
 
Two studies were performed in random, representative population samples and were rated as ‘good’ quality, and sixty-one
studies were rated as ‘fair’ quality, of which 42 studies reported results stratified by smoking status for the outcomes of
interest and could be included in meta-analyses. The remaining 216 studies were rated as ‘poor’ quality (see Table 1).
 
Table 1. Characteristics of included studies.
Ref. Lead author
Date
published
Country
Sample
size
Study
setting
Median
(IQR)
Female
%
Current
smoker
%
Former
smokers
%
Current/former
smokers %
Never
smokers
%
Never/unknown
smokers %
1 Guan, Ni
2020-02-
28
China 1,099 Hospital
      47
(35-58)
41.9 12.5 1.9 - 84.3 -
2020-03-       49
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60 Guan, Liang
2020-03-
26
China 1,590 Hospital
      49
(33-64)
42.7 - - 7.0 93.0 -
61 Lian
2020-03-
25
China 788 Hospital
             
 NA
38.5 6.9 - - - -
62 Jin
2020-03-
24
China 651 Hospital
      46
(32-60)
49.2 6.3 - - - -
63 Chen
2020-03-
26
China 548 Hospital
      62
(44-70)
37.6 4.4 2.6 - - -
64 Zhou, Yu
2020-03-
11
China 191 Hospital
      56
(46-67)
38.0 5.8 - - - -
65 Mo
2020-03-
16
China 155 Hospital
      54
(53-66)
44.5 3.9 - - - -
66 Zhang, Dong
2020-02-
19
China 140 Hospital
     57^
(25-87)
46.3 1.4 5.0 - - -
67 Wan
2020-03-
21
China 135 Hospital
      47
(36-55)
46.7 6.7 - - - -
68 Liu, Tao
2020-02-
28
China 78 Hospital
      38
(33-57)
50.0 - - 6.4 - -
69 Huang, Wang
2020-01-
24
China 41 Hospital
      49
(41-58)
27.0 7.3 - - - -
70 Zhang, Cai
2020-03-
20
China 645 Hospital
             
 NA
49.1 6.4 - - - -
71 Guo
2020-03-
27
China 187 Hospital
      59
(45-73)
51.3 9.6 - - - -
72 Liu, Ming
2020-03-
12
China 41 Hospital
      39
(30-48)
58.5 9.8 - - - -
73 Huang, Yang
2020-03-
05
China 36 Hospital
      69
(60-78)
30.6 - - 11.1 - -
74 Xu
2020-03-
08
China 53 Hospital
             
 NA
47.2 11.3 - - - -
75 Li
2020-02-
12
China 17 Hospital
      45
(33-57)
47.1 17.6 - - - -
31 Rentsch
2020-04-
14
USA 3,528
Community
and
Hospital
      66
(60-70)
4.6 27.2 30.6 - 36.9 -
76 Hu
2020-03-
25
China 323 Hospital
     61^
(23-91)
48.6 - - 11.8 - -
77 Wang, Pan
2020-03-
24
China 125 Hospital
      41
(26-66)
43.2 - - 12.8 - -
78 Chow (US
CDC)
2020-03-
31
USA 7,162
Community
and
Hospital
             
 NA
- 1.3 2.3 - - -
79 Dong, Cao
2020-03-
20
China 9 Hospital
      44
(30-46)
66.7 11.1 - - - -
80 Kim
2020-04-
01
South
Korea
28 Hospital
      43
(30-56)
46.4 17.9 - - - -
81 Shi, Yu
2020-03-
18
China 487 Hospital
      46
(27-65)
46.8 - - 8.2 - -
82 Yang, Yu
2020-02-
24
China 52 Hospital
      60
(47-73)
37.0 3.8 - - - -
83 Argenziano
2020-05-
29
USA 1,000 Hospital
      63
(50-75)
40.4 4.9 17.9 - 77.2 -
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29 (50-75)
84 Solis
2020-04-
25
Mexico 650 Hospital
         46
(NA)
42.1 9.4 - - - -
85 Richardson
2020-04-
22
USA 5,700 Hospital
      63
(52-75)
39.7 - - 9.8 52.8 -
86 Fontanet
2020-04-
23
France 661
Community
and
Hospital
      37
(16-47)
62.0 10.4 - - - 89.6
87 Zheng, Gao
2020-04-
19
China 66 Hospital
       
47^
(NA)
25.8 12.1 - - - -
88 Liao, Feng
2020-04-
24
China 1,848 Hospital
      55
(48-61)
54.7 - - 0.4 - -
89 Gil-Agudo
2020-04-
24
Spain 7 Hospital
      68
(34-75)
28.6 - - 42.9 57.1 -
90 Shi, Ren
2020-04-
23
China 134 Hospital
      46
(34-58)
51.5 - - 10.4 - -
91 Hadjadj
2020-04-
23
France 50 Hospital
      55
(50-63)
22.0 2.0 18.0 - 80.0 -
92 Gold (US CDC)
2020-04-
20
USA 305 Hospital
             
 NA
50.5 5.2 - - - -
93 Yu, Cai
2020-04-
27
China 95 Hospital
             
 NA
44.2 8.4 - - - -
94 Zheng, Xiong
2020-04-
30
China 73 Hospital
       
43^
(NA)
45.2 - - 11.0 89.0 -
95 de la Rica
2020-05-
11
Spain 48 Hospital
     66^
(33-88)
33.0 - - 20.8 - -
96 Yin, Yang
2020-05-
10
China 106 Hospital
      73
(61-85)
39.6 - - 17.0 - -
97 Shi, Zuo
2020-05-
17
USA 172 Hospital
     63^
(44-82)
44.0 - - 26.2 - -
98 Cho
2020-05-
11
UK 322,341
Community
and
Hospital
             
 NA
49.2 14.2 21.4 - 64.4 -
99 Allenbach
2020-05-
08
France 152 Hospital
      77
(60-83)
31.1 - - 6.6 - -
100 Robilotti
2020-05-
08
USA 423 Hospital
             
 NA
50.0 2.1 37.6 - 58.6 -
101
The
Opensafely
Collaborative
2020-07-
01
UK 17,278,392
Community
and
Hospital
             
 NA
50.1 17.0 32.9 - 45.9 -
102 Borobia
2020-05-
06
Spain 2,226 Hospital
      61
(46-78)
52.0 7.1 - - - -
103 Giacomelli
2020-05-
06
Italy 233 Hospital
      61
(50-72)
31.9 - - 30.0 70.0 -
104 Shah
2020-05-
06
USA 316 Hospital
      63
(43-72)
48.1 16.5 17.7 - 42.1 -
105 Kolin
2020-05-
05
UK 502,536
Community
and
Hospital
    56.5
(48-64)
54.4 10.5 34.4 - 54.4 -
106 Lubetzky
2020-05-
08
USA 54 Hospital
      57
(29-83)
62.0 - - 22.2 - -
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08 (29-83)
107 Goyal
2020-04-
17
USA 393 Hospital
    62.2
(49-74)
39.3 5.1 - - - -
108 Feng
2020-04-
10
China 476 Hospital
      53
(40-64)
43.1 9.2 - - - -
109 Yao
2020-04-
24
China 108 Hospital
      52
(37-58)
60.2 3.7 - - - -
110 Sami
2020-05-
19
Iran 490 Hospital
    56.6
(41-71)
39.0 14.1 - - - 85.9
111 Almazeedi
2020-05-
15
Kuwait 1,096 Hospital
      41
(25-57)
19.0 4.0 - - - 96.0
112 Carillo-Vega
2020-05-
14
Mexico 10,544
Community
and
Hospital
   46.5^
(30-62)
42.3 8.9 - - - -
113 Yanover
2020-05-
13
Israel 4,353
Community
and
Hospital
      35
(22-54)
44.5 11.8 3.0 - 85.2 -
114 Hamer
2020-05-
13
UK 387,109 Hospital
    56.2
(48-64)
55.1 9.7 34.8 - 55.5 -
115 Regina
2020-05-
14
Switzerland 200 Hospital
      70
(55-81)
40.0 4.5 - - - -
116 de Lusignan
2020-05-
15
UK 3,802
Community
and
Hospital
      58
(34-73)
57.6 10.9 46.1 - 29.6 -
117 Targher
2020-05-
13
China 339 Hospital
     
48.4^
(NA)
52.8 8.3 - - - -
118 Valenti
2020-05-
18
Italy 789 Community
     
40.7^
(NA)
35.0 25.9 - - - -
119 Feuth
2020-05-
18
Finland 28 Hospital
      56
(47-72)
46.0 10.7 28.6 - 60.7 -
120 Ge
2020-05-
18
China 51 Hospital
      70
(58-79)
27.5 13.7 - - - -
121 Parrotta
2020-05-
18
USA 76
Community
and
Hospital
    44.9
(13-71)
61.8 2.6 26.3 - 68.4 -
122 Shekhar
2020-05-
18
USA 50 Hospital
    55.5
(20-85)
54.0 48.0 - - - -
123 Mejia-Vilet
2020-05-
16
Mexico 329 Hospital
      49
(41-60)
36.0 - - 7.0 - -
124 Chen, Jiang
2020-05-
16
China 135 Hospital
             
 NA
42.2 - - 9.6 - -
125 Li, Chen
2020-05-
16
China 1,008 Hospital
      55
(44-65)
43.6 5.7 - - - -
27 Rimland
2020-05-
19
USA 11 Hospital
      59
(48-65)
18.2 9.1 - - - -
126 Palaiodimos
2020-05-
15
USA 200 Hospital
    64
(50-
73.5)
51.0 - - 32.5 67.5 -
127 Ip
2020-05-
25
USA 2,512 Hospital
      64
(52-76)
37.6 3.1 17.8 - 64.5 -
2020-05-       62
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128 Heili-Frades
2020-05-
25
Spain 4,712 Hospital
      62
(47-77)
50.5 4.9 17.4 - - 66.5
129 Vaquero-
Roncero
2020-05-
24
Spain 146 Hospital
     66^
(59-72)
32.2 - - 6.8 - -
130 Kim, Garg
2020-05-
22
USA 2,491 Hospital
      62
(50-75)
46.8 6.0 25.8 - - 68.1
131 Wu
2020-05-
21
Italy 174 Hospital
   61.2^
(50-71)
30.5 - - 33.3 - -
132 Shi, Zhao
2020-05-
20
China 101 Hospital
      71
(59-80)
40.6 - - 5.0 - -
133 Al-Hindawi
2020-05-
20
UK 31 Hospital
         61
(NA)
12.9 3.2 71.0 - 25.8 -
134 Basse
2020-05-
19
France 141 Hospital
      62
(52-72)
72.0 17.7 - - - -
135 Freites
2020-05-
19
Spain 123 Hospital
 
59.88^
(44-74)
69.9 3.3 - - - -
136 Alshami
2020-05-
19
Saudi
Arabia
128
Quarantine
Centre
   39.6^
(24-55)
53.9 15.6 2.3 - - -
137 Berumen
2020-05-
26
Mexico 102,875 Hospital
             
 NA
49.1 - - 9.6 - 90.4
138 Gianfrancesco
2020-05-
29
Multiple 600
Community
and
Hospital
      56
(45-67)
71.0 - - 21.5 64.8 -
139 Li, Long
2020-05-
28
China 145 Not Stated
     49^
(13-80)
61.0 - - 5.5 - -
140 Batty
2020-06-
17
UK 908 Hospital
 
57.27^
(48-66)
44.3 11.2 - - - -
141 Israel
2020-06-
01
Israel 24,906
Community
and
Hospital
      40
(27-59)
48.7 16.8 12.7 - 70.5 -
142 del Valle
2020-05-
30
USA 1,484 Hospital
      62
(52-72)
40.6 5.5 23.3 - - -
143 Chaudhry
2020-05-
29
USA 40
Community
and
Hospital
    52
(45.5-
61)
60.0 - - 15.0 - -
144 Louis
2020-05-
28
USA 22 Hospital
   66.5^
(55-77)
36.4 - - 45.5 - -
145 Soto-Mota
2020-06-
05
Mexico 400 Hospital
             
 NA
30.0 - - 12.0 - -
146 Garibaldi
2020-05-
26
USA 832 Hospital
      63
(49-75)
47.0 5.5 22.6 - - -
147 Docherty
2020-05-
22
Multiple 20,133 Hospital
    72.9
(58-82)
40.0 4.2 21.7 - 44.5 -
148 Boulware
2020-06-
03
Multiple 821 Community
      40
(33-50)
51.6 3.3 - - - -
149 Kuderer
2020-05-
28
Multiple 928
Community
and
Hospital
      66
(57-76)
50.0 4.6 35.1 - 50.5 -
150 Romao
2020-06-
08
Portugal 34 Community
     41^
(26-66)
67.7 - - 26.5 - -
Community
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151 Giannouchos
2020-06-
07
Mexico 236,439
Community
and
Hospital
   42.5^
(25-59)
49.1 9.1 - - - 90.9
152 Ramlall
2020-06-
06
USA 11,116
Community
and
Hospital
  52
(34.7-
69.5)
55.2 - - 26.8 73.2 -
153 Wang, Oekelen
2020-06-
05
USA 58
Community
and
Hospital
         67
(NA)
48.0 - - 36.2 - -
154 Perrone
2020-06-
05
Italy 1,189 Hospital
             
 NA
21.2 - - 21.9 - -
155 Sharma
2020-06-
05
India 501 Hospital
   35.1^
(18-51)
36.0 - - 4.2 - -
156 Eugen-Olsen
2020-06-
02
Denmark 407 Hospital
      64
(47-77)
57.7 20.6 36.9 - 39.6 -
157 Martinez-
Portilla
2020-06-
02
Mexico 224
Community
and
Hospital
      29
(26-33)
100.0 - - 3.1 - -
158 Raisi-
Estabragh
2020-06-
02
UK 4,510 Hospital
             
 NA
48.8 - - 51.8 - -
159 Luo
2020-06-
02
China 625 Hospital
         46
(NA)
47.7 3.0 - - - -
160 Houlihan
2020-06-
09
UK 200 Community
      34
(29-44)
61.0 11.0 16.5 - 66.5 -
161 Cen
2020-06-
08
China 1,007 Hospital
      61
(49-68)
51.0 - - 8.7 - -
162 Klang
2020-05-
23
USA 3,406 Hospital
             
 NA
61.8 - - 23.3 - -
163 Maraschini
2020-06-
12
Italy 146 Hospital
   32.5^
(27-38)
100.0 - 9.6 - 80.8 -
164 Wang, Zhong
2020-06-
12
USA 7,592
Community
and
Hospital
             
 NA
45.1 3.6 17.1 - 51.9 -
165 McQueenie
2020-06-
12
UK 428,199
Community
and
Hospital
             
 NA
54.9 - - 44.4 55.0 -
26 Miyara
2020-06-
12
France 479
Community
and
Hospital
             
 NA
44.7 6.7 31.6 - 59.5 -
166 Apea
2020-06-
12
UK 1,737 Hospital
     
63.4^
(NA)
30.4 - - 10.0 - -
167 Woolford
2020-06-
11
UK 4,510
Community
and
Hospital
     
 70.5
(NA)
51.2 13.0 38.1 - 48.1 -
168 Hultcrantz
2020-06-
11
USA 127
Community
and
Hospital
      68
(41-91)
46.0 - - 26.8 72.4 -
169 Rajter
2020-06-
10
USA 280 Hospital
   59.6^
(41-77)
45.5 5.7 10.7 - 74.6 -
170 Lan
2020-06-
09
USA 104 Community
     49^
(34-63)
47.1 - - 24.0 - -
171 Zeng
2020-06-
16
China 1,031 Hospital
   60.3^
(46-74)
47.8 - - 10.2 - -
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16 (46-74)
172 Suleyman
2020-06-
16
USA 463 Hospital
   57.5^
(40-74)
55.9 - - 34.6 - -
173 Chen, Yu
2020-06-
16
China 1,859 Hospital
      59
(45-68)
50.0 2.4 3.6 - 94.0 -
174 Garassino
2020-06-
12
Multiple 200
Community
and
Hospital
    68
(61.8-
75)
30.0 24.0 55.5 - 18.5 -
175 Hernandez-
Garduno
2020-06-
11
Mexico 32,583
Community
and
Hospital
      45
(34-56)
48.7 - - 11.0 - 88.8
176 Govind
2020-06-
20
UK 6,309
Community
and
Hospital
   46.5^
(31-61)
38.3 66.3 26.8 - 5.5 -
177 Siso-Almirall
2020-06-
20
Spain 322
Community
and
Hospital
   56.7^
(38-74)
50.0 - - 25.2 - -
178 Gu
2020-06-
18
USA 5,698
Community
and
Hospital
     47^
(26-67)
62.0 7.0 24.7 - 50.8 -
179 Kibler
2020-06-
16
France 702
Community
and
Hospital
     82^
(75-88)
56.0 3.7 - - - -
180 Ikitimur
2020-06-
03
Turkey 81 Hospital
     55^
(38-72)
44.0 - - 28.4 - -
181 Sierpinski
2020-06-
03
Poland 1,942 Community
         50
(NA)
60.0 6.3 - - - 49.7
182 Zhou, He
2020-06-
10
China 238 Hospital
    55.5
(35-67)
57.0 2.9 - - - -
183 Crovetto
2020-06-
19
Spain 874
Community
and
Hospital
   33.7^
(28-38)
100.0 1.1 - - - 13.2
184 Veras
2020-06-
09
Brazil 32 Hospital
   58.9^
(40-77)
47.0 - - 25.0 - -
185 Sterlin
2020-06-
11
France 135 Hospital
      61
(50-72)
41.0 3.7 38.5 - 57.8 -
186 Rossi
2020-06-
09
France 246 Hospital
     68^
(53-83)
39.0 - - 25.2 - -
187 Duan
2020-06-
22
China 616 Hospital
      64
(53-70)
57.5 3.7 - - - -
188 Martin-Jimenez
2020-06-
09
Spain 339 Hospital
    81.6
(72-87)
39.5 - - 30.7 - -
189 Elezkurtaj
2020-06-
17
Germany 26 Hospital
  70
(61.8-
78.3)
34.6 - - 19.2 - -
190 Lenka
2020-06-
22
USA 32 Hospital
   62.2^
(51-73)
37.5 - - 50.0 - -
191 Olivares
2020-06-
16
Chile 21 Hospital
     61^
(26-85)
76.2 - - 9.5 - -
192 Salton
2020-06-
20
Italy 173 Hospital
     
64.4^
(NA)
34.9 - - 29.5 - -
193 Wei
2020-06-
USA 147 Hospital
     52^
41.0 14.3 - - - -
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193 Wei
18
USA 147 Hospital
(34-70)
41.0 14.3 - - - -
194 Zuo, Estes
2020-06-
17
China 172 Hospital
     61^
(25-95)
44.0 - - 26.2 - -
195 Killerby
2020-06-
17
USA 531
Community
and
Hospital
    51.6
(38-62)
57.1 - - 17.1 71.4 -
196 Petrilli
2020-05-
22
USA 5,279
Community
and
Hospital
      54
(38-66)
51.5 5.5 17.1 - 61.9 -
197 Magagnoli
2020-06-
05
USA 807 Hospital
      70
(60-75)
4.3 - - 15.9 - -
33 Niedzwiedz
2020-05-
29
UK 392,116
Community
and
Hospital
             
 NA
54.9 9.8 34.8 - 55.4 -
198 Bello-Chavolla
2020-05-
31
Mexico 177,133
Community
and
Hospital
    42.6
(26-59)
48.9 - - 9.3 - -
199 Zuo, Yalavarthi
2020-04-
24
USA 50 Hospital
      61
(46-76)
34.0 - - 36.0 - -
200 Sigel
2020-06-
28
USA 493 Hospital
      60
(55-67)
24.1 - - 28.6 - -
201 Nguyen
2020-06-
29
USA 689
Community
and
Hospital
      55
(40-68)
57.0 - - 24.8 - -
202 de Melo
2020-06-
29
Brazil 181 Hospital
   55.3^
(34-76)
60.8 9.9 12.2 - 38.1 -
203 Auvinen
2020-06-
29
Finland 61 Hospital
      53
(41-67)
36.0 18.0 27.9 - 54.1 -
204 Souza
2020-06-
28
Brazil 8,443 Hospital
             
 NA
53.0 - - 1.7 - 96.3
205 Mendy
2020-06-
27
USA 689
Community
and
Hospital
49.5
(35.2-
67.5)
47.0 - - 24.7 - -
206 Pongpirul
2020-06-
26
Thailand 193 Hospital
      37
(29-53)
41.5 - - 15.0 66.3 -
207 Jin, Gu
2020-06-
25
China 6 Hospital
   60.5^
(51-75)
33.3 33.3 - - - -
208 Fisman
2020-06-
23
Canada 21,922
Community
and
Hospital
             
 NA
57.0 - - 2.3 - -
209 Madariaga
2020-06-
23
USA 103
Community
and
Hospital
   41.8^
(27-55)
48.5 - - 25.2 74.8 -
210 Senkal
2020-07-
07
Turkey 611 Hospital
     57^
(18-98)
40.6 11.3 - - - -
211 Mohamud
2020-07-
02
USA 6 Hospital
   65.8^
(55-78)
16.7 - - 16.7 - -
212 Magleby
2020-06-
30
USA 678 Hospital
      68
(50-81)
38.9 - - 28.6 - -
213 Kimmig
2020-07-
06
USA 111 Hospital
     63^
(48-78)
44.1 7.2 36.0 - 56.8 -
214 Bello-Chavolla,
Antonio-Villa
2020-07-
04
Mexico 60,121
Community
and
   45.5^
(29-61)
47.0 - - 10.5 - -
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214
Antonio-Villa 04
Mexico 60,121 and
Hospital
(29-61)
47.0 - - 10.5 - -
215 Zacharioudakis
2020-07-
04
USA 314 Hospital
      64
(54-72)
34.7 - - 22.8 - -
216 Antonio-Villa
2020-07-
04
Mexico 34,263
Community
and
Hospital
     40^
(29-50)
62.9 9.7 - - - -
217 Patel
2020-07-
03
USA 129 Hospital
   60.8^
(47-74)
45.0 37.2 - - - 55.8
218 Merzon
2020-07-
03
Israel 7,807
Community
and
Hospital
     
46.2^
(NA)
58.6 - - 16.2 - -
34 Trubiano
2020-07-
02
Australia 2,935
Community
and
Hospital
      39
(29-53)
63.5 - - 8.8 - -
219 Fan
2020-07-
11
UK 1,425
Community
and
Hospital
             
 NA
46.7 12.2 40.1 - 46.9 -
220 Shi,
Resurreccion
2020-07-
11
UK 1,521
Community
and
Hospital
 61.5^
(57-
66.8)
45.9 - - 54.9 - -
221 Maucourant
2020-07-
10
Sweden 27 Hospital
      57
(18-78)
22.2 11.1 25.9 - 40.7 -
222 Elmunzer
2020-07-
09
Multiple 1,992 Hospital
     60^
(43-76)
43.0 6.3 28.6 - 59.0 -
223 Alizadehsani
2020-07-
09
Iran 319 Hospital
 
45.48^
(26-63)
55.5 - - 0.3 - -
224 Xie
2020-07-
07
China 619 Hospital
             
 NA
52.0 - - 8.2 - -
42 Merkely
2020-07-
17
Hungary 10,474 Community
   48.7^
(30-66)
53.6 28.0 20.5 - 51.4 -
225 Fox
2020-07-
17
UK 55
Community
and
Hospital
      63
(23-88)
31.0 1.8 10.9 - 56.4 -
66 Zhang, Cao
2020-07-
14
China 289 Hospital
      57
(22-88)
46.6 3.5 6.2 - - -
226 Martinez--
Resendez
2020-07-
20
Mexico 8 Hospital
      57
(48-69)
25.0 - - 12.5 - -
227 Hoertel
2020-07-
20
France 12,612 Hospital
   58.7^
(39-77)
49.6 - - 9.3 - -
228 Mcgrail
2020-07-
19
USA 209 Hospital
     
 62.5
(NA)
38.8 - - 18.7 - -
229 Pandolfi
2020-07-
17
Italy 33 Hospital
      62
(52-65)
21.1 3.0 24.2 - 72.7 -
28 Girardeau
2020-07-
17
France 10 Community
      30
(29-33)
50.0 40.0 10.0 - - -
230 Kurashima
2020-07-
17
Japan 53 Hospital
   62.9^
(49-76)
35.8 - - 50.9 - -
231 Zhan
2020-07-
16
China 75 Hospital
      57
(25-75)
48.0 - - 12.0 - -
232 Omrani
2020-07-
Qatar 1,409
Community
and
      39
17.2 - - 9.2 - -
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232 Omrani
2020-07-
16
Qatar 1,409 and
Hospital
      39
(30-50)
17.2 - - 9.2 - -
233 Gupta
2020-07-
16
USA 496 Hospital
      70
(60-78)
46.0 - - 7.3 - 31.7
97 Shi, Zuo
2020-07-
15
USA 172 Hospital
 
61.48^
(25-96)
44.0 - - 26.2 - -
234 Hussein
2020-07-
15
USA 502 Hospital
   60.9^
(45-76)
52.0 9.0 22.1 - - 68.9
235 Bian
2020-07-
15
China 28 Hospital
     56^
(42-67)
42.9 7.1 - - - -
236 Eiros
2020-07-
14
Spain 139
Community
and
Hospital
      52
(41-57)
72.0 4.3 50.4 - - -
237 Marcos
2020-07-
14
Spain 918 Hospital
   72.8^
(58-87)
42.2 6.1 - 15.3 - -
238 Hoertel,
Sanchez-Rico
2020-07-
14
France 7,345 Hospital
             
 NA
49.3 8.5 - - - -
239 Soares
2020-07-
16
Brazil 10,713
Community
and
Hospital
             
 NA
55.0 2.0 - - - 98.0
240 Zobairy
2020-07-
28
Iran 203
Community
and
Hospital
   49.2^
(32-65)
44.8 5.9 - - - 94.1
241 Altamimi
2020-07-
27
Qatar 68 Hospital
     49^
(40-58)
2.0 16.4 - - - 83.6
242 Thompson
2020-07-
27
UK 470 Hospital
      71
(57-82)
46.0 14.0 27.2 - 58.7 -
243 Reiter
2020-07-
26
Austria 235 Community
   44.2^
(32-55)
70.0 22.6 22.6 - 54.7 -
244 Motta
2020-07-
26
USA 374 Hospital
   64.7^
(46-82)
41.4 - - 33.2 66.8 -
245 Santos
2020-07-
25
USA 43
Community
and
Hospital
      50
(34-73)
63.0 - - 4.7 - -
246 Schneeweiss
2020-07-
22
USA 24,313
Community
and
Hospital
     67^
(53-80)
53.0 - - 2.9 - -
247 Concha-Mejia
2020-07-
24
Colombia 72
Community
and
Hospital
      46
(28-64)
47.0 8.3 11.1 - - -
248 Izquierdo
2020-07-
24
Spain 71,192
Community
and
Hospital
     42^
(18-66)
59.0 10.0 - - - 90.0
249 Bernaola
2020-07-
21
Spain 1,645 Hospital
             
 NA
38.5 2.5 10.9 - 86.6 -
30 Islam
2020-08-
18
Bangladesh 1,016
Community
and
Hospital
      37
(28-49)
35.9 18.2 - - - -
250 Qi
2020-03-
03
China 267 Hospital
      48
(35-65)
45.2 19.9 - - - 80.1
251 Peters
2020-08-
15
Netherlands 1,893 Hospital
   66.8^
(52-81)
39.4 4.9 - - - -
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252 Ouyang
2020-08-
14
China 217 Hospital
   46.5^
(30-62)
53.5 16.6 - - - -
57 Ward
2020-08-
21
UK 99,908 Community
             
 NA
56.1 10.6 - - - 88.4
253 Valenzuela
2020-08-
14
Chile 29 Hospital
   56.9^
(43-70)
6.9 17.2 - - - 82.8
254 Monteiro
2020-08-
14
USA 112 Hospital
      61
(45-74)
34.0 6.2 17.9 - 68.8 -
255 Philipose
2020-08-
14
UK 466 Hospital
       67
(6-97)
41.8 6.0 73.2 - 16.5 -
256 Weerahandi
2020-08-
14
USA 394 Community
      63
(55-70)
37.0 5.3 25.9 - 55.8 -
29 Ebinger
2020-08-
04
USA 6,062 Community
   41.5^
(29-53)
67.8 1.7 - - - -
257 Altibi
2020-08-
11
USA 706 Hospital
   66.7^
(51-81)
43.0 4.0 37.3 - 58.8 -
258 Izzi-Engbeaya
2020-08-
11
UK 889 Hospital
   65.8^
(48-83)
40.0 - - 21.3 33.2 -
259 Rizzo
2020-08-
11
USA 76,819 Hospital
      54
(38-67)
55.2 6.7 20.8 - 50.4 -
260 Dashti
2020-08-
04
USA 4,140
Community
and
Hospital
      52
(36-65)
55.0 - - 28.4 51.6 -
261 Morshed
2020-08-
02
Bangladesh 103 Community
      37
(31-53)
28.2 31.1 - - - 68.9
262 Jun
2020-08-
01
USA 3,086 Hospital
      66
(56-77)
40.9 3.7 21.3 - 52.8 -
263 Higuchi
2020-07-
30
Japan 57 Hospital
      52
(35-70)
43.9 12.3 29.8 - 57.9 -
264 Zhou, Sun
2020-07-
29
China 144 Hospital
      47
(38-56)
46.5 9.0 - - - 91.0
265 Salerno
2020-08-
22
USA 15,920 Hospital
      49
(30-65)
57.0 - - 36.8 55.9 -
266 Kumar
2020-07-
29
India 91 Hospital
     47^
(41-52)
21.0 44.0 - - - -
267 Hao
2020-06-
01
China 788 Hospital
      46
(35-56)
48.4 6.9 - - - -
268 Iversen
2020-08-
03
Denmark 28,792
Community
and
Hospital
   44.4^
(31-57)
78.9 16.0 6.5 - 76.8 -
269 Hippisley-Cox
2020-07-
13
UK 8,275,949
Community
and
Hospital
   48.5^
(30-66)
50.3 17.2 21.4 - 57.3 -
270 Fillmore
2020-08-
24
USA 22,914
Community
and
Hospital
             
 NA
- 37.5 40.7 - 15.5 -
271 Rashid
2020-08-
22
UK 517 Hospital
   72.8^
(59-86)
31.9 9.9 29.0 - 29.4 -
272 Pan
2020-08-
22
USA 12,084
Community
and
Hospital
   45.5^
(27-63)
54.3 - - 17.5 - -
2020-08-
Community
   34.8^
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273 Alkurt
2020-08-
20
Turkey 932
Community
and
Hospital
   34.8^
(25-44)
64.4 24.5 - - - -
274 Zhao, Chen
2020-07-
30
USA 641 Hospital
         60
(NA)
40.1 21.7 - - - -
275 Holman
2020-08-
13
UK 10,989
Community
and
Hospital
             
 NA
38.8 5.5 42.6 - 49.0 -
276 Qu
2020-07-
29
China 246 Hospital
   53.6^
(38-68)
53.3 42.3 - - - -
277 Chand
2020-08-
19
USA 300 Hospital
   58.2^
(45-70)
39.3 22.3 - - - -
278 Oliveira
2020-08-
31
USA 131 Hospital
  61
(49.5-
71.5)
64.9 - - 17.6 26.7 -
279 Hussein, Galal
2020-09-
01
Egypt 444 Community
   33.1^
(21-45)
56.8 13.1 9.0 - 77.9 -
280 Vilar-Garcia
2020-09-
01
Spain 7,699,568
Community
and
Hospital
      43
(24-59)
50.9 17.1 - - - -
281 Ibarra, Nava
2020-09-
01
Mexico 416,546
Community
and
Hospital
             
NA
46.9 7.4 - - - -
282 Ibrahim
2020-08-
27
USA 38 Hospital
     63^
(51-75)
47.0 10.5 - - - -
283 Rubio-Rivas
2020-09-
01
Spain 186 Hospital
   64.3^
(51-77)
30.6 4.3 20.4 - 75.3 -
284 Mamtani
2020-09-
02
USA 403 Hospital
     55^
(41-68)
32.3 9.7 12.7 - 68.5 -
285 Ren
2020-09-
02
China 432 Hospital
             
 NA
57.9 10.0 - - 90.0 -
286 Yoo
2020-08-
31
USA 4,840 Hospital
66.4
(54.9-
77.8)
43.5 4.4 21.4 - 53.3 -
287 Mutambudzi
2020-09-
03
UK 120,075
Community
and
Hospital
             
 NA
54.2 11.7 26.4 - 61.9 -
288 Yan
2020-09-
07
China 578 Hospital
   49.2^
(35-63)
49.3 9.2 - - - -
289 Mancilla-
Galindo
2020-09-
08
Mexico 183,779
Community
and
Hospital
     45^
(28-61)
46.0 7.6 - - - -
290 Ullah
2020-09-
08
UK 212
Community
and
Hospital
66.7
(54.2-
80.5)
44.8 11.3 48.1 - 37.7 -
260 Dashti
2020-09-
13
USA 12,347
Community
and
Hospital
      47
(32-62)
53.3 4.6 15.9 - 57.1 -
291 Nicholson
2020-09-
17
USA 1,042 Hospital
      64
(53-75)
43.2 8.3 22.2 - 37.1 -
292 Ariza
2020-09-
18
Colombia 351
Community
and
Hospital
     
 30.5
(NA)
54.0 6.8 - - - 93.2
43 Carrat
2020-09-
France 14,628 Community
             
60.3 12.0 40.8 - 45.6 -
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43 Carrat
2020-09-
18
France 14,628 Community
             
 NA
60.3 12.0 40.8 - 45.6 -
293 Zhu
2020-09-
21
China 432
Community
and
Hospital
      49
(35-60)
47.9 14.4 - - - -
294 Sun
2020-08-
16
USA 323
Community
and
Hospital
             
 NA
57.6 - - 39.3 - 60.7
295 Kalan
2020-05-
01
Iran 193 Hospital
   52.6^
(37-67)
36.3 7.3 - - 85.0 -
296 Burrell
2020-09-
16
Australia 204 Hospital
    63.5
(53-72)
31.4 - - 13.2 - 82.8
297 Meini
2020-09-
23
Italy 461 Hospital
             
 NA
51.2 10.4 25.8 - 63.8 -
298 Favara
2020-09-
20
UK 434 Community
      40
(19-66)
82.0 8.5 - - - 91.5
299 da Silva Neto
2020-09-
23
Brazil 91
Community
and
Hospital
     49^
(29-68)
49.4 - - 19.8 - 80.2
300 Li, Cai
2020-09-
28
China 98 Hospital
    68.5
(63-75)
58.2 - - 11.2 - 88.8
301 Wang
2020-09-
29
USA 1,078 Hospital
             
 NA
38.2 3.7 24.9 - 49.0 -
302 Lopez-
Medrano
2020-09-
30
Spain 261 Hospital
             
 NA
43.7 - - 37.2 - 62.8
303 Incerti
2020-10-
02
USA 13,658 Hospital
      62
(49-75)
48.1 6.3 22.6 - 45.4 -
304 Collard
2020-10-
01
Netherlands 1,604 Hospital
   65.7^
(50-80)
39.5 4.9 - - - -
305 Robinson
2020-10-
05
USA 3,248 Hospital
     51^
(34-68)
72.0 4.0 17.6 - 61.8 -
306 Erber
2020-10-
06
Germany 4,554 Community
     
38.5^
(NA)
70.4 - - 18.0 - 82.0
307 Chaudhary
2020-10-
06
Nepal 220 Hospital
    31.5
(25-37)
17.7 11.4 7.7 - 80.0 -
308 Roederer
2020-10-
09
France 818 Community
             
 NA
20.4 36.9 8.8 - 53.9 -
309 Savarraj
2020-10-
18
USA 48 Hospital
     50^
(33-67)
48.0 10.4 - - - -
310 Israel, Schaffer
2020-10-
18
Israel 26,959 Hospital
             
 NA
50.6 6.8 15.2 - 77.0 -
311 El-Solh
2020-10-
20
USA 7,816 Hospital
      69
(60-74)
5.5 - - 45.3 - 54.7
312 Chudasama
2020-10-
23
UK 1,706
Community
and
Hospital
      68
(48-85)
42.5 13.8 41.0 - 45.3 -
313 Salama
2020-10-
23
Multiple 377 Hospital
   55.9^
(41-70)
40.8 5.8 17.0 - 77.2 -
314 Makaronidis
2020-10-
01
UK 567 Community
   39.4^
(27-51)
69.1 9.3 - - - 90.7
315 Ramachandran
2020-10-
12
USA 188 Hospital
             
 NA
- 18.6 - - - -
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12  NA
316 Hadi
2020-08-
05
USA 370
Community
and
Hospital
   48.2^
(34-62)
29.5 - - 15.1 84.9 -
317 Luo, Rizvi
2020-10-
03
USA 102 Hospital
      68
(61-75)
52.0 - - 26.5 - 73.5
318 Ioannou
2020-09-
23
USA 88,747
Community
and
Hospital
             
 NA
9.0 20.6 37.5 - 29.3 -
319 ISARIC
2020-10-
04
Multiple 88,463 Hospital
         72
(NA)
43.0 - - 5.2 - 37.6
320 Perico
2020-10-
22
Italy 423 Community
   44.3^
(34-54)
36.4 21.7 18.0 - 60.3 -
321 Lamure
2020-10-
12
France 89 Hospital
      67
(19-92)
34.0 5.6 32.6 - 48.3 -
322 Yadaw
2020-10-
01
USA 5,051
Community
and
Hospital
             
NA
- 3.6 15.9 - 51.4 -
Note. – Age not provided for total sample; ^ Denotes mean (SD). * This study was rated as ‘poor’ quality as the manuscript
only presents data for current (but not former) smokers despite having obtained complete smoking status, thus resulting in
>20% missing data on smoking status.
 
Smoking prevalence by country
 
Unadjusted smoking prevalence compared with overall estimates for national adult smoking prevalence split by country
and study setting is presented in Figure 2a and 2b. Lower than expected current smoking prevalence was generally
observed, especially in studies with hospitalised samples. Former smoking prevalence was more similar to expected
prevalence when reported; however, prevalence was typically higher than national estimates. National smoking
prevalence estimates used for comparison are presented in Supplementary table 3.
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Figure 2a. Weighted mean prevalence of current smoking in included studies, split by country (solid
lines). The circles represent individual studies, with colour corresponding to study setting (i.e.
community, community and hospital, hospital) and size corresponding to relative study sample size.
For comparison, national current smoking prevalence is shown by the dashed red lines. Countries
with three or more eligible studies are shown.
 
Figure 2b. Prevalence of former smoking in included studies, split by country (solid lines). The circles
represent individual studies, with colour corresponding to study setting (i.e. community, community
and hospital, hospital) and size corresponding to relative study sample size. For comparison, national
former smoking prevalence is shown by dashed red lines. Countries with three or more eligible
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studies are shown.
 
 
SARS-CoV-2 testing by smoking status
 
Three studies provided data on access to SARS-CoV-2 diagnostic testing for those meeting local testing criteria by
smoking status. In a cohort study of US military veterans aged 54-7531, current smokers were more likely to receive a test:
42.3% (1,603/3,789) of the sample were current smokers compared with 23.8% of all veterans aged 50+ years using any
tobacco product between 2010-201532. In the UK Biobank cohort33, a multivariable analysis showed former (RR = 1.29,
95% CI = 1.14-1.45, p < .001) and current (RR = 1.44, 95% CI = 1.20-1.71, p < .001) compared with never smokers to be
more likely to receive a test. In an Australian rapid assessment screening clinic for COVID-1934, 9.4% (397/4,226) of the
self-referred sample (subsequently assessed by a healthcare professional to decide on testing) were current smokers. Of
these self-referrals, healthcare professionals decided that current compared with former or never smokers were less likely
to require a test (RR = 0.93, 95% CI = 0.86-1.0, p = 0.045).
 
SARS-CoV-2 infection by smoking status
 
Fifty-five studies provided data on SARS-CoV-2 infection for people meeting local testing criteria by smoking status (see
Table 2). Meta-analyses were performed for two ‘good’ and 19 ‘fair’ quality studies (see Figure 3 and 4). Current smokers
were at reduced risk of testing positive for SARS-CoV-2 compared with never smokers (RR = 0.69, 95% CrI = 0.57-0.83, τ
= 0.38, 95% CI = 0.25-0.56). The probability of current smokers being at reduced risk of infection compared with never
smokers (RR ≤0.9) was 99.6%. Former compared with never smokers were at increased risk of testing positive, but data
were inconclusive (RR = 1.02, 95% CrI = 0.93-1.12, τ = 0.18, 95% CI = 0.12-0.26) and favoured there being no important
association. The probability of former smokers being at increased risk of infection (RR ≥1.1) compared with never smokers
was 5%. Results were materially unchanged in the two sensitivity analyses (see Supplementary figure S2).
 
Table 2. SARS-CoV-2 infection by smoking status. 
 SARS-CoV-2 negative SARS-CoV-2 positive
Author
Total
population
tested
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Never
smoker
(%)
Not
stated
(%)
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Never
smoker
(%)
Rentsch 3528
2974
(84.30%)
1444
(48.55%)
704
(23.67%)
-
826
(27.77%)
-
554
(15.70%)
159
(28.70%)
179
(32.31%)
-
216
(38.99%)
Fontanet 661
490
(74.13%)
64
(13.06%)
- -
426
(86.94%)
-
171
(25.87%)
5
(2.92%)
- -
166
(97.08%)
Cho 1331
793
(59.58%)
142
(17.91%)
214
(26.99%)
-
437
(55.11%)
-
538
(40.42%)
111
(20.63%)
145
(26.95%)
-
282
(52.42%)
Shah 243
212
(87.24%)
52
(24.53%)
47
(22.17%)
-
113
(53.30%)
-
29
(11.93%)
0
(0.00%)
9
(31.03%)
-
20
(68.97%)
805 141 307 354 669 72 285 303
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Kolin 1474
805
(54.61%)
141
(17.52%)
307
(38.14%)
-
354
(43.98%)
3 (0.37%)
669
(45.39%)
72
(10.76%)
285
(42.60%)
-
303
(45.29%)
de Lusignan 3291
2740
(83.26%)
366
(13.36%)
1450
(52.92%)
-
924
(33.72%)
-
551
(16.74%)
47
(8.53%)
303
(54.99%)
-
201
(36.48%)
Valenti 789
689
(87.33%)
197
(28.59%)
- - -
492
(71.41%)
40
(5.07%)
7
(17.50%)
- - -
Parrotta 76
39
(51.32%)
1
(2.56%)
10
(25.64%)
-
27
(69.23%)
1 (2.56%)
37
(48.68%)
1
(2.70%)
10
(27.03%)
-
25
(67.57%)
Berumen 102875
71353
(69.36%)
- - 7173 (10.05%)
64180
(89.95%)
-
31522
(30.64%)
- - 2748 (8.72%)
28774
(91.28%)
Israel 24906
20755
(83.33%)
3783
(18.23%)
2671
(12.87%)
-
14301
(68.90%)
-
41151
(165.23%)
406
(0.99%)
483
(1.17%)
-
3262
(7.93%)
del Valle 1108
143
(12.91%)
27
(18.88%)
53
(37.06%)
- -
63
(44.06%)
965
(87.09%)
55
(5.70%)
293
(30.36%)
- -
Romao 34
20
(58.82%)
- - 5 (25.00%) -
15
(75.00%)
14
(41.18%)
- - 4 (28.57%) -
Ramlall 11116
4723
(42.49%)
- - - - -
6393
(57.51%)
- -
1643.001
(25.70%)
4749.999
(74.30%)
Sharma 501
267
(53.29%)
- - 1 (0.37%) -
266
(99.63%)
234
(46.71%)
- - 20 (8.55%) -
Eugen-Olsen 407
290
(71.25%)
76
(26.21%)
104
(35.86%)
-
102
(35.17%)
-
117
(28.75%)
8
(6.84%)
46
(39.32%)
-
59
(50.43%)
Raisi-
Estabragh
4510
3184
(70.60%)
- - 1653 (51.92%) -
1531
(48.08%)
1326
(29.40%)
- - 683 (51.51%) -
Houlihan 177
97
(54.80%)
14
(14.43%)
14
(14.43%)
-
69
(71.13%)
-
80
(45.20%)
7
(8.75%)
19
(23.75%)
-
54
(67.50%)
McQueenie 428199
424355
(99.10%)
- -
189299
(44.61%)
235056
(55.39%)
-
1311
(0.31%)
- - 669 (51.03%)
642
(48.97%)
Woolford 4474
3161
(70.65%)
441
(13.95%)
1194
(37.77%)
-
1526
(48.28%)
-
1313
(29.35%)
145
(11.04%)
525
(39.98%)
-
643
(48.97%)
Lan 104
83
(79.81%)
- - 24 (28.92%) -
59
(71.08%)
21
(20.19%)
- - 1 (4.76%) -
Hernandez-
Garduno
32583
20279
(62.24%)
- - 2399 (11.83%)
17861
(88.08%)
-
12304
(37.76%)
- - 1191 (9.68%)
11083
(90.08%)
Govind 6215
6207
(99.87%)
4104
(66.12%)
1669
(26.89%)
-
342
(5.51%)
-
102
(1.64%)
78
(76.47%)
20
(19.61%)
-
2
(1.96%)
Gu 4699
3815
(81.19%)
360
(9.44%)
1142
(29.93%)
-
2313
(60.63%)
-
884
(18.81%)
40
(4.52%)
264
(29.86%)
-
580
(65.61%)
Kibler 702
680
(96.87%)
25
(3.68%)
- - -
655
(96.32%)
22
(3.13%)
1
(4.55%)
- - -
Petrilli 10620
5341
(50.29%)
3454
(64.67%)
816
(15.28%)
-
541
(10.13%)
530
(9.92%)
5279
(49.71%)
3268
(61.91%)
902
(17.09%)
-
288
(5.46%)
Bello-
Chavolla
150200
98567
(65.62%)
- - 9624 (9.76%) -
88943
(90.24%)
51633
(34.38%)
- - 4366 (8.46%) -
Auvinen 61
33
(54.10%)
10
(30.30%)
8
(24.24%)
-
15
(45.45%)
-
28
(45.90%)
1
(3.57%)
9
(32.14%)
-
18
(64.29%)
Favara 70
55
(78.57%)
5
(9.09%)
- - -
50
(90.91%)
15
(21.43%)
2
(13.33%)
- - -
Antonio-Villa 34263
23338
(68.11%)
2293
(9.83%)
- - -
21045
(90.17%)
10925
(31.89%)
1023
(9.36%)
- - -
Merzon 7807
7025
(89.98%)
- - 1136 (16.17%) -
5889
(83.83%)
782
(10.02%)
- - 127 (16.24%) -
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Merzon 7807
(89.98%)
- - 1136 (16.17%) -
(83.83%) (10.02%)
- - 127 (16.24%) -
Trubiano 2676
2827
(105.64%)
- - 256 (9.06%) -
2586
(91.48%)
108
(4.04%)
- - 3 (2.78%) -
Shi, 
 Resurreccion
1521
1265
(83.17%)
- - 681 (53.83%) -
584
(46.17%)
256
(16.83%)
- - 154 (60.16%) -
Riley 120620
120461
(99.87%)
2594
(2.15%)
- -
19914
(16.53%)
97953
(81.32%)
159
(0.13%)
3
(1.89%)
- -
17
(10.69%)
Alizadehsani 319
196
(61.44%)
- - - -
196
(100.00%)
123
(38.56%)
- - 1 (0.81%) -
Merkely 10474
10336
(98.68%)
2904
(28.10%)
2107
(20.39%)
-
5310
(51.37%)
15
(0.15%)
70
(0.67%)
16
(22.86%)
15
(21.43%)
-
38
(54.29%)
Mcgrail 209
118
(56.46%)
- - 31 (26.27%) -
87
(73.73%)
91
(43.54%)
- - 8 (8.79%) -
Izquierdo 71192
NA (
NA%)
- - - - -
1006
(1.41%)
111
(11.03%)
- - -
Ward 99908
94416
(94.50%)
10202
(10.81%)
- - -
84214
(89.19%)
5492
(5.50%)
433
(7.88%)
- - -
Ebinger 6062
5850
(96.50%)
99
(1.69%)
- - -
5668
(96.89%)
212
(3.50%)
3
(1.42%)
- - -
Salerno 15920
14753
(92.67%)
- - 5517 (37.40%)
8278
(56.11%)
958
(6.49%)
1167
(7.33%)
- - 339 (29.05%)
626
(53.64%)
Iversen 28792
27629
(95.96%)
4430
(16.03%)
1799
(6.51%)
-
21217
(76.79%)
246
(0.89%)
1163
(4.04%)
177
(15.22%)
78
(6.71%)
-
898
(77.21%)
Hippisley-
Cox
8275949
NA (
NA%)
- - - - -
19486
(0.24%)
1354
(6.95%)
5715
(29.33%)
-
12036
(61.77%)
Fillmore 22914
21120
(92.17%)
8137
(38.53%)
8416
(39.85%)
-
3227
(15.28%)
1340
(6.34%)
1794
(7.83%)
452
(25.20%)
899
(50.11%)
-
322
(17.95%)
Alkurt 119
NA (
NA%)
- - - - -
119
(100.00%)
14
(11.76%)
- - -
Ariza 351
322
(91.74%)
21
(6.52%)
- - -
301
(93.48%)
29
(8.26%)
3
(10.34%)
- - -
Carrat 14393
13426
(93.28%)
1652
(12.30%)
5620
(41.86%)
-
6154
(45.84%)
-
967
(6.72%)
98
(10.13%)
353
(36.50%)
-
516
(53.36%)
Meini 461
243
(52.71%)
39
(16.05%)
66
(27.16%)
-
138
(56.79%)
-
218
(47.29%)
9
(4.13%)
53
(24.31%)
-
156
(71.56%)
Favara 434
354
(81.57%)
28
(7.91%)
- - -
326
(92.09%)
80
(18.43%)
9
(11.25%)
- - -
Erber 4554
4446
(97.63%)
- - 806 (18.13%) -
3640
(81.87%)
108
(2.37%)
- - 11 (10.19%) -
Roederer 815
390
(47.85%)
175
(44.87%)
32
(8.21%)
-
183
(46.92%)
-
425
(52.15%)
127
(29.88%)
40
(9.41%)
-
258
(60.71%)
Makaronidis 567
127
(22.40%)
16
(12.60%)
- - -
111
(87.40%)
440
(77.60%)
37
(8.41%)
- - -
Ioannou 88747
78616
(88.58%)
17138
(21.80%)
29245
(37.20%)
-
22327
(28.40%)
9906
(12.60%)
10131
(11.42%)
1135
(11.20%)
4073
(40.20%)
-
3647
(36.00%)
Perico 423
260
(61.47%)
69
(26.54%)
35
(13.46%)
-
156
(60.00%)
-
163
(38.53%)
23
(14.11%)
41
(25.15%)
-
99
(60.74%)
Note. Niedzwiedz et al. reported on SARS-CoV-2 infection by smoking status in multivariable analyses but did not present
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raw data. 
 
Figure 3. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers. *
Indicates ‘good’ quality studies. The prior from the previous review version (v8) was RR = 0.72.
Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers. *
Indicates ‘good’ quality studies. The prior from the previous review version (v8) was RR = 1.02.
Hospitalisation for COVID-19 by smoking status
 
Thirty-five studies examined hospitalisation for COVID-19 disease, stratified by smoking status (see Table 3). Meta-
analyses were performed for ten ‘fair’ quality studies (see Figure 5 and 6). Current (RR = 1.06, CrI = 0.89-1.27, τ = 0.23,
95% CI = 0.09-0.43) and former (RR = 1.17, CrI = 1.04-1.36, τ = 0.17, 95% CI = 0.08-0.32) compared with never smokers
were at increased risk of hospitalisation with COVID-19. However, data for current smokers were inconclusive and
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favoured there being no important association. The probability of current and former smokers being at increased risk of
hospitalisation (RR ≥1.1) compared with never smokers was 32% and 87%, respectively. Results were materially
unchanged in two sensitivity analyses (see Supplementary figure S3).
 
Table 3. Hospitalisation with COVID-19 by smoking status. 
 Community Hospitalised
Author
Population
with
outcome
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Never
smoker
(%)
Never/unknown
smoker (%)
Not
stated
(%)
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Rentsch 554
269
(48%)
69
(25.65%)
90
(33.46%)
-
110
(40.89%)
- -
285
(51%)
90
(31.58%)
89
(31.23%)
-
Chow (US
CDC)
6637
5143
(77%)
61
(1.19%)
80
(1.56%)
- - -
5002
(97.26%)
1494
(22%)
27
(1.81%)
78
(5.22%)
-
Argenziano 1000
151
(15%)
14
(9.27%)
18
(11.92%)
-
119
(78.81%)
- -
849
(84%)
35
(4.12%)
161
(18.96%)
-
Lubetzky 54
15
(27%)
- - 4 (26.67%) - -
11
(73.33%)
39
(72%)
- - 8 (20.51%)
Carillo-Vega 9946
3922
(39%)
408
(10.40%)
- - - -
3514
(89.60%)
6024
(60%)
486
(8.07%)
- -
Yanover 4353
4180
(96%)
484
(11.58%)
118
(2.82%)
-
3578
(85.60%)
- -
173
(3%)
30
(17.34%)
11
(6.36%)
-
Hamer 387109
386349
(99%)
37333
(9.66%)
134542
(34.82%)
-
214474
(55.51%)
- -
760
(0%)
93
(12.24%)
313
(41.18%)
-
Heili-Frades 4712
1973
(41%)
121
(6.13%)
222
(11.25%)
- - 1630 (82.62%)
1630
(82.62%)
2739
(58%)
112
(4.09%)
598
(21.83%)
-
Freites 123
69
(56%)
1
(1.45%)
- - - -
68
(98.55%)
54
(43%)
3
(5.56%)
- -
Berumen 102875
18832
(18%)
- - 1546 (8.21%) - 17286 (91.79%) -
12690
(12%)
- - 1202 (9.47%)
Gianfrancesco 600
323
(53%)
- - 61 (18.89%) - -
262
(81.11%)
277
(46%)
- - 68 (24.55%)
Chaudhry 40
19
(47%)
- - 0 (0.00%) - -
19
(100.00%)
21
(52%)
- - 6 (28.57%)
Giannouchos 89756
58485
(65%)
4679
(8.00%)
- - - 53806 (92.00%) -
31271
(34%)
2721
(8.70%)
- -
Wang,
Oekelen
57
22
(38%)
- - 6 (27.27%) - -
16
(72.73%)
36
(63%)
- - 15 (41.67%)
Miyara 470
132
(28%)
14
(10.61%)
41
(31.06%)
-
77
(58.33%)
- -
338
(71%)
18
(5.33%)
111
(32.84%)
-
Suleyman 463
108
(23%)
- - 23 (21.30%) - -
85
(78.70%)
355
(76%)
- - 137 (38.59%)
Garassino 196
48
(24%)
10
(20.83%)
27
(56.25%)
-
11
(22.92%)
- -
152
(77%)
38
(25.00%)
84
(55.26%)
-
Siso-Almirall 260
119
(45%)
- - 31 (26.05%) - -
88
(73.95%)
141
(54%)
- - 50 (35.46%)
Gu 884
511
(57%)
30
(5.87%)
126
(24.66%)
-
355
(69.47%)
- -
373
(42%)
10
(2.68%)
138
(37.00%)
-
Killerby 531
311
(58%)
- - 37 (11.90%)
222
(71.38%)
-
52
(16.72%)
220
(41%)
- - 54 (24.55%)
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Killerby 531
(58%)
- - 37 (11.90%)
(71.38%)
-
(16.72%) (41%)
- - 54 (24.55%)
Petrilli 5279
2538
(48%)
147
(5.79%)
337
(13.28%)
-
1678
(66.12%)
-
376
(14.81%)
2741
(51%)
141
(5.14%)
565
(20.61%)
-
Nguyen 689
333
(48%)
- - 57 (17.12%) - -
276
(82.88%)
356
(51%)
- - 114 (32.02%)
Mendy 689
473
(68%)
- - 84 (17.76%) - -
389
(82.24%)
216
(31%)
- - 86 (39.81%)
Soares 10713
9561
(89%)
132
(1.38%)
- - - 9429 (98.62%) -
1152
(10%)
77
(6.68%)
- -
Zobairy 203
65
(32%)
1
(1.54%)
- - - 64 (98.46%) -
138
(67%)
11
(7.97%)
- -
Izquierdo 1006
743
(73%)
52
(7.00%)
- - - 691 (93.00%) -
263
(26%)
16
(6.08%)
- -
Rizzo 76819
60039
(78%)
3931
(6.55%)
11379
(18.95%)
-
30042
(50.04%)
-
14687
(24.46%)
16780
(21%)
1254
(7.47%)
4585
(27.32%)
-
Dashti 4140
2759
(66%)
- - 600 (21.75%)
1541
(55.85%)
-
618
(22.40%)
1381
(33%)
- - 577 (41.78%)
Pan 12084
8548
(70%)
- - 1263 (14.78%) - -
7285
(85.22%)
3536
(29%)
- - 874 (24.72%)
Vilar-Garcia 328892
291254
(88%)
64792
(22.25%)
- - - -
226462
(77.75%)
37638
(11%)
9526
(25.31%)
- -
Ibarra-Nava 416546
302693
(72%)
26773
(8.84%)
- - - -
275920
(91.16%)
113853
(27%)
8875
(7.80%)
- -
Dashti 12347
8946
(72%)
353
(3.95%)
1099
(12.28%)
-
5133
(57.38%)
-
2361
(26.39%)
3401
(27%)
210
(6.17%)
860
(25.29%)
-
Da Silva Neto 91
44
(48%)
- - 4 (9.09%) - 40 (90.91%) -
47
(51%)
- - 14 (29.79%)
Israel,
Schaffer
26676
13706
(51%)
944
(6.89%)
2166
(15.80%)
-
10596
(77.31%)
- -
12970
(48%)
880
(6.78%)
1936
(14.93%)
-
Ioannou 10131
6624
(65%)
716
(10.81%)
2484
(37.50%)
-
2542
(38.38%)
-
882
(13.32%)
3507
(34%)
419
(11.95%)
1593
(45.42%)
-
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Figure 5. Forest plot for risk of hospitalisation in current vs. never smokers. The prior from the
previous review version (v8) was RR = 1.06.
Figure 6. Forest plot for risk of hospitalisation in former vs. never smokers. The prior from the
previous version (v8) was RR = 1.19.
Disease severity by smoking status
 
Sixty-five studies reported disease severity in hospitalised patients stratified by smoking status (see Table 4). Severe (as
opposed to non-severe) disease was broadly defined as requiring intensive treatment unit (ITU) admission, requiring
oxygen as a hospital inpatient or in-hospital death. Meta-analyses were performed for eight ‘fair’ quality studies (see Figure
7 and 8). Current (RR = 1.26, CrI = 0.86-1.94, τ = 0.34, 95% CI = 0.01-0.86) and former (RR = 1.52, CrI = 1.12-2.06, τ =
0.29, 95% CI = 0.05-0.65) compared with never smokers were at increased risk of greater disease severity; data for current
smokers were inconclusive but favoured there being a small but important association. The probability of current and
former smokers having increased risk of greater disease severity (RR ≥1.1) compared with never smokers was 80% and
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98%, respectively. Results were materially unchanged in two sensitivity analyses (see Supplementary figure S4).
 
Table 4. Disease severity by smoking status.
 Non severe disease Severe disease
Author
Population
with
severity
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Never
smoker
(%)
Never/unknown
smoker (%)
Not
stated
(%)
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Guan, Ni 1085
913
(84%)
108
(11.83%)
12
(1.31%)
-
793
(86.86%)
- -
172
(15%)
29
(16.86%)
9
(5.23%)
-
Zhang, Dong 9
3
(33%)
0 (0.00%)
3
(100.00%)
-
0
(0.00%)
- -
6
(66%)
2
(33.33%)
4
(66.67%)
-
Wan 9
8
(88%)
8
(100.00%)
0 (0.00%) -
0
(0.00%)
- -
1
(11%)
1
(100.00%)
0
(0.00%)
-
Huang,
Wang
3
3
(100%)
3
(100.00%)
0 (0.00%) -
0
(0.00%)
- - 0 (0%) 0 (-%) 0 (-%) -
Rentsch 285
168
(58%)
47
(27.98%)
53
(31.55%)
-
68
(40.48%)
- -
117
(41%)
43
(36.75%)
36
(30.77%)
-
Hu 323
151
(46%)
- - 12 (7.95%) - 139 (92.05%) -
172
(53%)
- - 26 (15.12%)
Wang, Pan 125
100
(80%)
- - 9 (9.00%) - 91 (91.00%) -
25
(20%)
- - 7 (28.00%)
Kim 27
21
(77%)
3
(14.29%)
- - - 18 (85.71%) -
6
(22%)
2
(33.33%)
0
(0.00%)
-
Shi, Yu 474
425
(89%)
- - 34 (8.00%) - 391 (92.00%) -
49
(10%)
- - 6 (12.24%)
Liao, Feng 148
92
(62%)
- - 5 (5.43%) - -
87
(94.57%)
56
(37%)
3 (5.36%) - -
Shi, Ren 134
88
(65%)
- - 8 (9.09%) - -
80
(90.91%)
46
(34%)
- - 6 (13.04%)
Hadjadj 50
15
(30%)
1 (6.67%)
2
(13.33%)
-
12
(80.00%)
- -
35
(70%)
0 (0.00%)
7
(20.00%)
-
Zheng, Xiong 73
43
(58%)
- - 6 (13.95%)
37
(86.05%)
- -
30
(41%)
- - 2 (6.67%)
de la Rica 48
26
(54%)
- - 6 (23.08%) - -
20
(76.92%)
20
(41%)
- - 4 (20.00%)
Yin, Yang 106
47
(44%)
- - 6 (12.77%) - -
41
(87.23%)
59
(55%)
- - 12 (20.34%)
Allenbach 147
100
(68%)
- - 9 (9.00%) - -
91
(91.00%)
47
(31%)
- - 0 (0.00%)
Goyal 393
263
(66%)
14
(5.32%)
- - - -
249
(94.68%)
130
(33%)
6 (4.62%) - -
Feng 454
333
(73%)
27
(8.11%)
- - - -
306
(91.89%)
121
(26%)
17
(14.05%)
- -
Yao 108
83
(76%)
1 (1.20%) - - - -
82
(98.80%)
25
(23%)
3
(12.00%)
- -
Sami 490
400
(81%)
53
(13.25%)
- - - -
347
(86.75%)
90
(18%)
16
(17.78%)
- -
Regina 200
163
(81%)
9 (5.52%) - - - -
154
(94.48%)
37
(18%)
0 (0.00%) - -
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Feuth 28
21
(75%)
1 (4.76%)
7
(33.33%)
-
13
(61.90%)
- -
7
(25%)
2
(28.57%)
1
(14.29%)
-
Mejia-Vilet 329
214
(65%)
- - 13 (6.07%) - -
201
(93.93%)
115
(34%)
- - 10 (8.70%)
Chen, Jiang 135
54
(40%)
- - 4 (7.41%) - -
50
(92.59%)
81
(60%)
- - 9 (11.11%)
Vaquero-
Roncero
146
75
(51%)
- - 4 (5.33%) - -
71
(94.67%)
71
(48%)
- - 6 (8.45%)
Kim, Garg 2490
1692
(67%)
112
(6.62%)
395
(23.35%)
- - 1185 (70.04%) -
798
(32%)
38
(4.76%)
247
(30.95%)
-
Wu 174
92
(52%)
- - 47 (51.09%) - 45 (48.91%) -
82
(47%)
11
(13.41%)
- -
Chaudhry 40
34
(85%)
- - 5 (14.71%) - -
29
(85.29%)
6
(15%)
- - 1 (16.67%)
Garibaldi 832
532
(63%)
25
(4.70%)
107
(20.11%)
- - -
400
(75.19%)
300
(36%)
21
(7.00%)
81
(27.00%)
-
Kuderer 928
686
(73%)
35
(5.10%)
210
(30.61%)
-
370
(53.94%)
-
29
(4.23%)
242
(26%)
8 (3.31%)
116
(47.93%)
-
Romao 14
14
(100%)
- - 4 (28.57%) - -
10
(71.43%)
0 (0%) - - -
Giannouchos 89756
78050
(86%)
6322
(8.10%)
- - - 71728 (91.90%) -
11706
(13%)
1089
(9.30%)
- -
Cen 1007
720
(71%)
- - 70 (9.72%) - -
650
(90.28%)
287
(28%)
- - 18 (6.27%)
Maraschini 132
89
(67%)
-
11
(12.36%)
-
78
(87.64%)
- -
43
(32%)
-
3
(6.98%)
-
Siso-Almirall 260
212
(81%)
- - 60 (28.30%) - -
152
(71.70%)
48
(18%)
- - 21 (43.75%)
Gu 884
511
(57%)
30
(5.87%)
126
(24.66%)
-
355
(69.47%)
- -
134
(15%)
3 (2.24%)
61
(45.52%)
-
Petrilli 2729
1739
(63%)
97
(5.58%)
325
(18.69%)
-
1067
(61.36%)
-
250
(14.38%)
990
(36%)
44
(4.44%)
236
(23.84%)
-
Mendy 689
598
(86%)
- - 133 (22.24%) - -
465
(77.76%)
91
(13%)
- - 37 (40.66%)
Pongpirul 193
161
(83%)
- - 25 (15.53%)
106
(65.84%)
-
30
(18.63%)
32
(16%)
- - 4 (12.50%)
Jin, Gu 6
2
(33%)
- - 0 (0.00%) - -
4
(200.00%)
4
(66%)
- - 2 (50.00%)
Senkal 611
446
(73%)
48
(10.76%)
- - - -
398
(89.24%)
165
(27%)
21
(12.73%)
- -
Patel 129
89
(68%)
26
(29.21%)
- - - 58 (65.17%) 5 (5.62%)
40
(31%)
22
(55.00%)
- -
Maucourant 27
10
(37%)
1
(10.00%)
2
(20.00%)
-
2
(20.00%)
-
5
(50.00%)
17
(62%)
2
(11.76%)
5
(29.41%)
-
Xie 619
469
(75%)
- - 32 (6.82%) - -
437
(93.18%)
150
(24%)
- - 19 (12.67%)
Fox 55
30
(54%)
1 (3.33%)
4
(13.33%)
-
17
(56.67%)
-
8
(26.67%)
25
(45%)
0 (0.00%)
2
(8.00%)
-
Zhang, Cao 240
162
(67%)
2 (1.23%) 6 (3.70%) - - -
154
(95.06%)
78
(32%)
4 (5.13%)
4
(5.13%)
-
10 7 43
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Kurashima 53
10
(18%)
- - 3 (30.00%) - -
7
(70.00%)
43
(81%)
- - 24 (55.81%)
Zhan 75
NA
(NA%)
- - - - - -
75
(100%)
- - 9 (12.00%)
Omrani 858
806
(93%)
- - 121 (15.01%) - -
685
(84.99%)
52
(6%)
- - 9 (17.31%)
Marcos 918
555
(60%)
38
(6.85%)
- 69 (12.43%) - -
448
(80.72%)
363
(39%)
18
(4.96%)
- 71 (19.56%)
Hoertel,
Sanchez-
Rico
7345
6014
(81%)
433
(7.20%)
- - - -
5581
(92.80%)
1331
(18%)
190
(14.27%)
- -
Qi 267
217
(81%)
22
(10.14%)
- - - 195 (89.86%) -
50
(18%)
31
(62.00%)
- -
Monteiro 112
84
(75%)
3 (3.57%)
14
(16.67%)
-
63
(75.00%)
- 4 (4.76%)
28
(25%)
4
(14.29%)
6
(21.43%)
-
Dashti 1381
619
(44%)
- - 239 (38.61%)
292
(47.17%)
-
88
(14.22%)
762
(55%)
- - 338 (44.36%)
Morshed 103
87
(84%)
28
(32.18%)
- - - 59 (67.82%) -
16
(15%)
4
(25.00%)
- -
Zhou, Sun 144
108
(75%)
11
(10.19%)
- - - -
97
(89.81%)
36
(25%)
2 (5.56%) - -
Hippisley-
Cox
- NA - - - - - - 1286 
56
(4.35%)
427
(33.20%)
-
Zhao, Chen 641
398
(62%)
87
(21.86%)
- - - -
311
(78.14%)
195
(30%)
52
(26.67%)
- -
Qu 246
226
(91%)
90
(39.82%)
- - - -
136
(60.18%)
20
(8%)
14
(70.00%)
- -
Ren 432
314
(72%)
26
(8.28%)
- -
288
(91.72%)
- -
118
(27%)
17
(14.41%)
- -
Yan 578
450
(77%)
31
(6.89%)
- - - -
419
(93.11%)
128
(22%)
20
(15.62%)
- -
Nicholson 1042
550
(52%)
37
(6.73%)
106
(19.27%)
-
211
(38.36%)
-
196
(35.64%)
401
(38%)
41
(10.22%)
92
(22.94%)
-
Zhu 432
285
(65%)
46
(16.14%)
- - - -
239
(83.86%)
147
(34%)
16
(10.88%)
- -
Kalan 193
122
(63%)
9 (7.38%) - -
102
(83.61%)
-
11
(9.02%)
71
(36%)
5 (7.04%) - -
Burrell 204
85
(41%)
- - 7 (8.24%) - 75 (88.24%) 3 (3.53%)
119
(58%)
- - 20 (16.81%)
Chudasama 1706
NA
(NA%)
- - - - - -
1706
(100%)
235
(13.77%)
699
(40.97%)
-
Lamure 89
NA
(NA%)
- - - - - -
25
(28%)
1 (4.00%)
5
(20.00%)
-
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Figure 7. Forest plot for the risk of severe disease in current vs. never smokers. The prior from the
previous review version (v8) was RR = 1.25.
Figure 8. Forest plot for the risk of severe disease in former vs. never smokers. The prior from the
previous review version (v8) was RR = 1.52.
Mortality by smoking status
 
Sixty-two studies reported mortality from COVID-19 by smoking status (see Table 5), with 13 ‘fair’ quality studies included
in meta-analyses (see Figure 9 and 10). Current (RR = 1.05, 95% CrI = 0.71-1.49, τ = 0.45, 95% CI = 0.17-0.85) and former
(RR = 1.39, 95% CrI = 1.16-1.69, τ = 0.23, 95% CI = 0.05-0.44) compared with never smokers were at increased risk of in-
hospital mortality from COVID-19. However, data for current smokers were inconclusive and favoured there being no
important association. The probability of current and former smokers being at greater risk of in-hospital mortality (RR ≥1.1)
compared with never smokers was 39% and 99%, respectively. Results were materially unchanged in two sensitivity
analyses (see Supplementary figure S5).
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Table 5. Mortality by smoking status.
 Recovered Died
Author
Population
with
mortality
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Never
smoker
(%)
Never/unknown
smoker (%)
Not
stated
(%)
N (%)
Current
smoker
(%)
Former
smoker
(%)
Current/former
smoker (%)
Chen 274
161
(58%)
5
(3.11%)
5
(3.11%)
- - -
151
(93.79%)
113
(41%)
7
(6.19%)
2
(1.77%)
-
Zhou, Yu 191
137
(71%)
6
(4.38%)
- - - -
131
(95.62%)
54
(28%)
5
(9.26%)
- -
Yang, Yu 52
20
(38%)
2
(10.00%)
- - - 18 (90.00%) -
32
(61%)
- - -
Borobia 2226
1766
(79%)
113
(6.40%)
- - - -
1653
(93.60%)
460
(20%)
44
(9.57%)
- -
Giacomelli 233
185
(79%)
- - 53 (28.65%)
132
(71.35%)
- -
48
(20%)
- - 17 (35.42%)
Yao 108
96
(88%)
1
(1.04%)
- - - -
95
(98.96%)
12
(11%)
3
(25.00%)
- -
Carillo-Vega 9946
8983
(90%)
795
(8.85%)
- - - -
8188
(91.15%)
963
(9%)
99
(10.28%)
- -
Heng 51
39
(76%)
6
(15.38%)
- - - -
33
(84.62%)
12
(23%)
1
(8.33%)
- -
Chen, Jiang 135
NA
(NA%)
- - - - - -
31
(22%)
- - 4 (12.90%)
Heili-Frades 4712
4086
(86%)
210
(5.14%)
659
(16.13%)
- - 3217 (78.73%) -
626
(13%)
23
(3.67%)
161
(25.72%)
-
Kim, Garg 2490
2070
(83%)
128
(6.18%)
481
(23.24%)
- - 1461 (70.58%) -
420
(16%)
22
(5.24%)
161
(38.33%)
-
Al-Hindawi 31
15
(48%)
0
(0.00%)
10
(66.67%)
-
5
(33.33%)
- -
16
(51%)
1
(6.25%)
12
(75.00%)
-
Louis 22
16
(72%)
- - 7 (43.75%) - -
9
(56.25%)
6
(27%)
- - 3 (50.00%)
Soto-Mota 400
200
(50%)
- - 23 (11.50%) - -
177
(88.50%)
200
(50%)
- - 25 (12.50%)
Garibaldi 747
634
(84%)
36
(5.68%)
129
(20.35%)
- - -
469
(73.97%)
113
(15%)
6
(5.31%)
36
(31.86%)
-
Docherty 13364
8199
(61%)
370
(4.51%)
1832
(22.34%)
-
4179
(50.97%)
-
1818
(22.17%)
5165
(38%)
214
(4.14%)
1350
(26.14%)
-
Kuderer 928
807
(86%)
38
(4.71%)
262
(32.47%)
-
425
(52.66%)
-
31
(3.84%)
121
(13%)
5
(4.13%)
64
(52.89%)
-
Ramlall 11116
10498
(94%)
- - 2771 (26.40%)
7727
(73.60%)
- -
618
(5%)
- - 208 (33.66%)
Wang,
Oekelen
57
43
(75%)
- - 14 (32.56%) - -
29
(67.44%)
14
(24%)
- - 7 (50.00%)
Martinez-
Portilla
224
217
(96%)
- - 7 (3.23%) - -
210
(96.77%)
7 (3%) - - 0 (0.00%)
Cen 1007
964
(95%)
- - 87 (9.02%) - -
877
(90.98%)
43
(4%)
- - 1 (2.33%)
Klang 3406
2270
(66%)
- - 492 (21.67%) - -
1778
(78.33%)
1136
(33%)
- - 301 (26.50%)
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Klang 3406
(66%)
- - 492 (21.67%) - -
(78.33%) (33%)
- - 301 (26.50%)
Wang, Zhong 5510
4874
(88%)
247
(5.07%)
1083
(22.22%)
-
3544
(72.71%)
- -
636
(11%)
28
(4.40%)
214
(33.65%)
-
Miyara 338
211
(62%)
13
(6.16%)
58
(27.49%)
-
141
(66.82%)
- -
46
(13%)
1
(2.17%)
23
(50.00%)
-
Rajter 255
209
(81%)
- - 28 (13.40%)
181
(86.60%)
- -
53
(20%)
- - 18 (33.96%)
Zeng 1031
866
(84%)
- - 69 (7.97%) - -
797
(92.03%)
165
(16%)
- - 36 (21.82%)
Chen, Yu 1859
1651
(88%)
32
(1.94%)
54
(3.27%)
-
1565
(94.79%)
- -
208
(11%)
13
(6.25%)
12
(5.77%)
-
Garassino 190
124
(65%)
- - 92 (74.19%)
32
(25.81%)
- -
66
(34%)
-
61
(92.42%)
-
Gu 884
864
(97%)
40
(4.63%)
250
(28.94%)
-
219
(25.35%)
- -
20
(2%)
0
(0.00%)
14
(70.00%)
-
Sigel 88
70
(79%)
- - 37 (52.86%) - -
33
(47.14%)
18
(20%)
- - 11 (61.11%)
Nguyen 356
308
(86%)
- - 91 (29.55%) - -
217
(70.45%)
45
(12%)
- - 23 (51.11%)
de Souza 8443
7826
(92%)
- - 95 (1.21%) - 7571 (96.74%)
160
(2.04%)
617
(7%)
- - 47 (7.62%)
Mendy 532
663
(124%)
- - 160 (24.13%) - -
502
(75.72%)
26
(4%)
- - 10 (38.46%)
Shi, 
 Resurreccion
256
210
(82%)
- - 128 (60.95%) - -
82
(39.05%)
46
(17%)
- - 26 (56.52%)
Xie 619
591
(95%)
- - 43 (7.28%) - -
548
(92.72%)
28
(4%)
- - 8 (28.57%)
Fox 54
35
(64%)
1
(2.86%)
4
(11.43%)
-
18
(51.43%)
-
12
(34.29%)
19
(35%)
0
(0.00%)
2
(10.53%)
-
Zhang, Cao 289
240
(83%)
10
(4.17%)
6
(2.50%)
- - -
224
(93.33%)
49
(16%)
4
(8.16%)
8
(16.33%)
-
Gupta 496
255
(51%)
- - 15 (5.88%) - 80 (31.37%)
160
(62.75%)
241
(48%)
- - 21 (8.71%)
Soares 1075
696
(64%)
38
(5.46%)
- - - 658 (94.54%) -
456
(42%)
39
(8.55%)
- -
Thompson 470
301
(64%)
39
(12.96%)
79
(26.25%)
-
183
(60.80%)
- -
169
(35%)
27
(15.98%)
49
(28.99%)
-
Bernaola 1645
1382
(84%)
35
(2.53%)
146
(10.56%)
-
1201
(86.90%)
- -
263
(15%)
6
(2.28%)
33
(12.55%)
-
Islam 654
631
(96%)
103
(16.32%)
- - - -
507
(80.35%)
23
(3%)
3
(13.04%)
- -
Philipose 466
267
(57%)
19
(7.12%)
204
(76.40%)
-
44
(16.48%)
- -
199
(42%)
9
(4.52%)
137
(68.84%)
-
Dashti 4140
3953
(95%)
- - 1068 (27.02%)
2078
(52.57%)
-
804
(20.34%)
187
(4%)
- - 109 (58.29%)
Fillmore 1794
1566
(87%)
408
(26.05%)
758
(48.40%)
-
279
(17.82%)
-
98
(6.26%)
228
(12%)
44
(19.30%)
141
(61.84%)
-
Pan 3536
3302
(93%)
- - 862 (26.11%) - -
2440
(73.89%)
234
(6%)
- - 82 (35.04%)
Zhao, Chen 474
398
(83%)
87
(21.86%)
- - - -
311
(78.14%)
82
(17%)
36
(43.90%)
- -
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Holman 10989
NA
(NA%)
- - - - - -
10989
(100%)
609
(5.54%)
4684
(42.62%)
-
Chand 300
143
(47%)
23
(16.08%)
- - - -
120
(83.92%)
157
(52%)
44
(28.03%)
- -
Oliveira 131
105
(80%)
- - 16 (15.24%) - 83 (79.05%)
6
(5.71%)
26
(19%)
- - 7 (26.92%)
Vilar-Garcia 328892
316605
(96%)
71215
(22.49%)
- - - -
245390
(77.51%)
12287
(3%)
3103
(25.25%)
- -
Ibarra-Nava 416546
370038
(88%)
27001
(7.30%)
- - - -
343037
(92.70%)
46508
(11%)
3817
(8.21%)
- -
Rubio-Rivas 186
147
(79%)
7
(4.76%)
32
(21.77%)
-
108
(73.47%)
- -
39
(20%)
1
(2.56%)
6
(15.38%)
-
Ren 432
289
(66%)
25
(8.65%)
- -
264
(91.35%)
- -
143
(33%)
18
(12.59%)
- 125 (87.41%)
Ullah 212
158
(74%)
22
(13.92%)
67
(42.41%)
-
63
(39.87%)
-
6
(3.80%)
54
(25%)
2
(3.70%)
35
(64.81%)
-
Dashti 3401
2892
(85%)
190
(6.57%)
689
(23.82%)
-
1756
(60.72%)
-
257
(8.89%)
509
(14%)
20
(3.93%)
171
(33.60%)
-
Nicholson 1040
829
(79%)
70
(8.44%)
163
(19.66%)
-
320
(38.60%)
-
276
(33.29%)
211
(20%)
16
(7.58%)
68
(32.23%)
-
Kalan 193
188
(97%)
14
(7.45%)
- -
162
(86.17%)
-
12
(6.38%)
5 (2%)
0
(0.00%)
- -
Incerti 13658
11495
(84%)
785
(6.83%)
2450
(21.31%)
-
5450
(47.41%)
2810 (24.45%) -
2163
(15%)
81
(3.74%)
642
(29.68%)
-
Ioannou 10131
9033
(89%)
1054
(11.67%)
3549
(39.29%)
-
3339
(36.96%)
-
1091
(12.08%)
1098
(10%)
81
(7.38%)
528
(48.09%)
-
Lamure 89
59
(66%)
4
(6.78%)
16
(27.12%)
-
31
(52.54%)
-
8
(13.56%)
30
(33%)
1
(3.33%)
13
(43.33%)
-
Yadaw 5051
4635
(91%)
162
(3.50%)
709
(15.30%)
-
2394
(51.65%)
-
1370
(29.56%)
416
(8%)
17
(4.09%)
105
(25.24%)
-
Note. Solis et al. and the OpenSAFELY Collaborative reported on mortality by smoking status in a multivariable  analysis
but did not present raw data for both the exposure and outcome variables.
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Figure 9. Forest plot for the risk of mortality in current vs. never smokers. The prior from the previous
review version (v8) was RR = 1.1.
Figure 10. Forest plot for the risk of mortality in former smokers vs. never smokers. The prior from
the previous version (v8) was RR = 1.35.
 
Discussion
 
This living rapid review found uncertainty in the majority of 279 studies arising from the recording of smoking status.
Notwithstanding these uncertainties, compared with overall adult national prevalence estimates, recorded current smoking
rates in most studies were lower than expected. In a subset of better-quality studies (n = 21), current but not former smokers
had a reduced risk of testing positive for SARS-CoV-2 but current smokers appeared somewhat more likely to present for
testing and/or receive a test. Data for current smokers on the risk of hospitalisation, disease severity and mortality were
inconclusive, and favoured there being no important associations with hospitalisation and mortality and a small but
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important increase in the risk of severe disease. Former smokers were at increased risk of hospitalisation, disease severity
and mortality compared with never smokers.
 
Issues complicating interpretation
 
Interpretation of results from studies conducted during the first phase of the SARS-CoV-2 pandemic is complicated by
several factors (see Figure 11):
 
1) Exposure to SARS-CoV-2
i. Exposure to the SARS-CoV-2 virus is heterogeneous with different subgroups at heightened risk of infection at different
stages of the pandemic, at least partly due to differential contact matrices by age, sex and socioeconomic position35, which
are associated with smoking status.
ii. The probability of viral exposure depends largely on local prevalence, which varies over time. This likely introduces bias
in studies assessing the rate of infection by smoking status conducted in the early phase of the pandemic.
 
2) Infection with SARS-CoV-2
i. Infection following viral exposure depends on individual differences in, for example, genetic susceptibility or
immunocompetence, which are poorly understood at present. For example, the household secondary attack rate for
COVID-19 is estimated at 17%36.  
ii. Heated and humidified air may act to disrupt the ability of the virus to persist in the airway mucosa of smokers. There is
some evidence that transient localised hyperthermia can inhibit replication of rhinoviruses, a non-enveloped virus that
causes the common cold37. However, as SARS-CoV-2 is an enveloped virus38, it is unclear whether a similar protective
effect against viral replication or invasion by heated and humidified air may occur.
 
3) Symptomatic COVID-19
i. An estimated 20% (95% CI = 17-25%) of COVID-19 cases are asymptomatic39, with some evidence suggesting younger
people are more likely to be asymptomatic40. Testing is hence likely limited in some subgroups, with the potential for these
groups to include an overrepresentation of current smokers.
ii. Current and former smokers may be more likely to meet local criteria for community testing due to increased prevalence
of symptoms consistent with SARS-CoV-2 infection, such as cough, increased sputum production or altered sense of smell
or taste41. Evidence from a small number of studies indicates that current smokers may be more likely to present for testing,
hence increasing the denominator in comparisons with never smokers and potentially inflating the rate of negative tests in
current smokers. Infection positivity rates estimated among random samples are more informative. We identified one
population study conducted in Hungary reporting on seroprevalence and smoking status42; however, the response rate
was only 58.8% and the current smoking rate was 10 percentage points below national prevalence estimates, which raises
some doubt about representativeness of the final sample. Similarly, a second representative population survey with results
from three regions in France43 reported a current smoking rate of more than 10 percentage points below national
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prevalence (12% vs. 25% daily smoking prevalence)44.
 
4) Testing positive for SARS-CoV-2
i. Smokers with COVID-19 may be less likely to receive a SARS-CoV-2 test or present to hospital due to lack of access to
healthcare and may be more likely to die in the community from sudden complications (i.e. self-selection bias) and thus not
be recorded48. 
ii. Diagnostic criteria for SARS-CoV-2 infection and COVID-19 have changed during the course of the pandemic49. It was
not possible to extract details on the specific RT-PCR or antibody-based techniques or platforms used across the included
studies due to reporting gaps. Different platforms have varying sensitivity and specificity to detect SARS-CoV-2 infection.
In addition, testing for acute infection requires swabbing of the mucosal epithelium, which may be disrupted in current
smokers, potentially altering the sensitivity of assays47. 
 
5) Hospitalisation with COVID-19
i. Reasons for hospitalisation vary by country and time in the pandemic. For example, early cases may have been
hospitalised for isolation and quarantine reasons and not due to medical necessity. It is plausible this may have skewed
early data towards less severe cases. In addition, the observed association between former smoking and greater disease
severity may be explained by collider bias52, where conditioning on a collider (e.g. testing or hospitalisation) by design or
analysis may introduce a spurious association between current or former smoking (a potential cause of testing or
hospitalisation) and SARS-CoV-2 infection/adverse outcomes from COVID-19 (potentially exacerbated by smoking)53.  
ii. The majority of included studies relied on EHRs as the source of information on smoking status. Research shows large
discrepancies between EHRs and actual behaviour50. Known failings of EHRs include implausible longitudinal changes,
such as former smokers being recorded as never smokers at subsequent hospital visits50. Misreporting on the part of the
patient (perhaps due to perceived stigma) has also been observed, with biochemical measures showing higher rates of
smoking compared with self-report in hospitalised patients in the US51. It is hence possible that under-reporting of current
and former smoking status in hospitals occurred across the included studies. 
iii. The majority of included studies were conducted in hospital settings. It is plausible that a non-trivial proportion of
patients were infected with SARS-CoV-2 while being an inpatient for a different medical reason. If so, this may have
biased the hospitalised populations towards older and more frail groups, who are less likely to be smokers54.
iv. Individuals with severe COVID-19 symptoms may have stopped smoking immediately before admission to hospital and
may therefore not have been recorded as current smokers (i.e. reverse causality). 
 
6) COVID-19 disease severity and death
i. Given lack of knowledge of the disease progression and long-term outcomes of COVID-19, it is unclear whether studies
conducted thus far in the pandemic have monitored patients for a sufficient time period to report complete survival
outcomes or whether they are subject to early censoring. Adding to this, COVID-19 related mortality has been differentially
defined across countries and epidemic phases. For example, in some UK reporting, death within 28 days of a COVID-19
diagnosis is required for attributing the cause of death to the virus. However, according to the UK Office for National
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Statistics, COVID-19 deaths are recorded only if this was stated on the death certificate. 
ii. If there is a protective effect of nicotine on COVID-19 disease outcomes, abrupt nicotine withdrawal upon hospitalisation
may lead to worse disease outcomes including death12.
iii. During periods of heightened demand of limited healthcare resources, current and former smokers with extensive
comorbidities may have reduced priority for intensive care admission, thus leading to higher in-hospital mortality.
iv. COVID-19 outcomes are currently limited to in-hospital death or survival to discharge. This binary outcome does not
capture potential long-term morbidity attributed to COVID-19, such as stroke, amputation or acute cardiac events, which
may be moderated by smoking status.
 
Figure 11. A schematic of some of the interpretation issues for the association of smoking status and
COVID-19 infection, hospitalisation, disease severity and mortality. Numbers refer to the issues
listed in the above section. Issues on the right-hand side relate explicitly to smoking status.
Limitations
 
This living rapid evidence review was limited by having a single reviewer extracting data with a second independently
verifying the data extracted to minimise errors, restricting the search to one electronic database and one pre-print server
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and by not including at least three large population surveys due to their reliance on self-reported suspected or confirmed
SARS-CoV-2 infection (which means they do not meet our eligibility criteria)41,55,56. We also did not include a large, UK-
based, representative seroprevalence study57 in our meta-analyses as the odds of testing positive in former smokers was
not reported. However, the odds of infection for current smokers (OR = 0.64, 95% CI = 0.58-0.71) was in concordance with
the pooled estimate in our meta-analysis. Population surveys – particularly with linked data on confirmed infection or
antibodies – will be included in future review versions to help mitigate some of the limitations of healthcare based
observational studies. The comparisons of current and former smoking prevalence in the included studies with national
prevalence estimates did not adjust observed prevalence for the demographic profile of those tested/admitted to hospital.
Other reviews focused on this comparison have applied adjustments for sex and age, and continue to find lower than
expected prevalence – notwithstanding the issues complicating interpretation described above17.
 
Implications for research, policy and practice
 
Further scientific research is needed to resolve the mixed findings summarised in our review. First, clinical trials of the
posited therapeutic effect of nicotine could have important implications both for smokers and for improved understanding of
how the SARS-CoV-2 virus causes disease in humans. Such trials should focus on medicinal nicotine (as smoked
tobacco is a dirty delivery mechanism that could mask beneficial effects) and potentially differentiate between different
modes of delivery (i.e. inhaled vs. ingested) since this can affect pharmacokinetics58 and potential therapeutic effects. A
second research priority would be a large, representative (randomly sampled) population survey with a validated
assessment of smoking status which distinguishes between recent and long-term ex-smokers – ideally biochemically
verified – and assesses seroprevalence and links to health records.
 
In the meantime, public-facing messages about the possible protective effect of smoking or nicotine are premature. In our
view, until there is further research, the quality of the evidence does not justify the huge risk associated with a message
likely to reach millions of people that a lethal activity, such as smoking, may protect against COVID-19. It continues to be
appropriate to recommend smoking cessation and emphasise the role of alternative nicotine products to support smokers
to stop as part of public health efforts during COVID-19. At the very least, smoking cessation reduces acute risks from
cardiovascular disease and could reduce demands on the healthcare system59. GPs and other healthcare providers can
play a crucial role – brief, high-quality and free online training is available at National Centre for Smoking Cessation and
Training.
 
Conclusion
 
Across 279 studies, recorded current but not past smoking prevalence was generally lower than national prevalence
estimates. Current smokers were at reduced risk of testing positive for SARS-CoV-2 and former smokers were at increased
risk of hospitalisation, disease severity and mortality compared with never smokers.
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